Pathology In Depth

Library › Blood bank immunohematology: blood group systems and pretransfusion testing

Blood bank immunohematology: blood group systems and pretransfusion testing

Last reviewed 2026-11-10 by a board-certified pathologist. 152 references.

ABO and H Blood Group Systems and ABO Discrepancies

Definition. The ABO system (ISBT 001) and the H system (ISBT 018) are carbohydrate blood group systems. The ABO gene at 9q34.2 encodes a glycosyltransferase that adds a sugar to the H antigen. The H antigen is made by α(1,2)-fucosyltransferases encoded by FUT1 and FUT2 at 19q13.33 (ISBT Table of blood group systems v12.0). The A-transferase adds N-acetylgalactosamine (GalNAc) and the B-transferase adds galactose (Gal) to H, producing the A and B antigens (Ogasawara et al. 2024). Group O individuals lack a functional transferase, so their red cells carry unconverted H antigen (Yamamoto et al. 1990). An ABO discrepancy is a disagreement between the red cell (forward) grouping and the plasma (reverse) grouping. It is resolved before the ABO group is reported (Desai et al. 2024).

Related page: The Rh Blood Group System: D, Weak and Partial D, RhCE Variants and Rh Typing Problems (D antigen, weak and partial D, RhD typing) Related page: Kell, Duffy, Kidd, MNS, Lewis, I, P1PK and Other Blood Group Systems, Nomenclature and Genotyping (Lewis, P1PK, I and protein-based systems) Related page: Immunohematology Methods in Red Cell Serology (hemagglutination, adsorption and elution, lectins) Related page: Pretransfusion Testing, Antibody Identification, Crossmatch and Drug Interference (type and screen, crossmatch, compatibility-testing regulations) Related page: Blood Component Selection and Serologic Workup of Autoantibodies (ABO selection of components, cold autoantibodies) Related page: Transfusion Reactions (acute hemolytic transfusion reaction from ABO incompatibility)

Blood group antibodies: naturally occurring and immune

Blood group antibodies form in two settings.

  • Naturally occurring antibodies arise without exposure to foreign red cells. Anti-A and anti-B are the main examples. Anti-A1, anti-P1 and anti-M are other naturally occurring antibodies, and most react best below 37 °C (Das et al. 2021; Hellberg et al. 2013; Tondon et al. 2008).
  • Immune antibodies arise after transfusion or pregnancy (Clausen and van der Schoot 2025). They are detected by the indirect antiglobulin test. Their clinical significance by blood group system is given in Kell, Duffy, Kidd, MNS, Lewis, I, P1PK and Other Blood Group Systems, Nomenclature and Genotyping.
  • Clinical significance is the potential of an antibody to shorten the survival of transfused antigen-positive red cells, to cause a transfusion reaction or to cause hemolytic disease of the fetus and newborn (HDFN) (Crottet 2018). ABO is the most important blood group system in transfusion medicine and transplantation (Ogasawara et al. 2024). ABO-incompatible transfusion causes acute hemolytic transfusion reactions (Transfusion Reactions).

ABO hemolytic disease of the fetus and newborn

  • Setting. ABO HDFN occurs almost exclusively in group A or group B fetuses of group O mothers (Ciobanu et al. 2020; Toshniwal et al. 2025). Maternal IgG crosses the placenta from about 13 weeks of gestation (Ciobanu et al. 2020).
  • Severity. ABO HDFN that needs intervention before birth is rare, because A and B antigens are not fully developed on fetal red cells and are also present on other cells, including the placenta (Ciobanu et al. 2020).
  • Frequency. ABO HDFN is confined to about 1% of group O women with high-titer IgG antibodies, and its reported incidence is 0.33–2.2% (Toshniwal et al. 2025). Among 139 group A or B newborns of group O mothers, 28 (20%) developed hyperbilirubinemia that required phototherapy. Maternal IgG anti-A or anti-B titers were 128 or higher in 79% of these 28 (Toshniwal et al. 2025).

Genetics and biochemistry of the ABO system

Feature Finding Source
Gene ABO, 9q34.2; seven exons across about 19.5 kb ISBT table v12.0; Ogasawara et al. 2024
A versus B allele Single-base substitutions that change four amino acids switch donor-sugar specificity Yamamoto et al. 1990
A-transferase product GalNAc added to H Ogasawara et al. 2024
B-transferase product Gal added to H Ogasawara et al. 2024
Common O allele Single-base deletion in exon 6 causes a frameshift and an inactive protein Yamamoto et al. 1990; Ogasawara et al. 2024
Allelic diversity More than 200 ABO alleles are classified Ogasawara et al. 2024
Tissue expression Erythroid and epithelial cells; absent in fibroblasts Ogasawara et al. 2024
  • Phenotypes and expected antibodies. The Landsteiner rule states that plasma contains anti-A or anti-B against the antigen the red cells lack (Hagman et al. 2024).
ABO group Red cell antigens Plasma antibodies Forward grouping (anti-A / anti-B) Reverse grouping (A1 cells / B cells)
A A Anti-B Positive / negative Negative / positive
B B Anti-A Negative / positive Positive / negative
AB A and B No anti-A or anti-B Positive / positive Negative / negative
O H only Anti-A and anti-B Negative / negative Positive / positive
  • Development of ABO antibodies. Anti-A and anti-B develop after exposure to intestinal bacteria from the age of 4–6 months. For that reason plasma (reverse) grouping is usually omitted for newborns (Desai et al. 2024). In an autoanalyzer series of 19,466 samples, neonates aged 1 year or younger accounted for 35.3% of rejected ABO results, mostly from weak reverse reactions (Lim et al. 2022).
  • Expression in myeloid neoplasms. Weak A expression on red cells is documented in acute myeloid leukemia. Loss of ABH antigens is frequent in myelodysplastic syndrome and myeloproliferative neoplasms (Ogasawara et al. 2024).

The H system: FUT1, FUT2 and secretor status

  • Two fucosyltransferases. FUT1 encodes the H enzyme that makes H antigen on red cells. FUT2 encodes the secretor enzyme that makes H antigen in secretory epithelia and saliva. The two genes share about 70% DNA sequence similarity and lie 35 kb apart (Soejima and Koda 2023).
  • Secretors. A secretor carries at least one functional FUT2 allele and secretes A, B and H substances in saliva according to the ABO genotype. Nonsecretors make up about 25% of many populations (Soejima and Koda 2023). Saliva inhibition testing determines secretor status (Byrne et al. 2019).
  • Amount of H antigen by ABO group. Group O red cells carry the most H antigen and A1B red cells the least, in the order O > A2 > B > A2B > A1 > A1B (Lahare et al. 2024). Reactivity with Ulex europaeus lectin (anti-H) follows this order.

Bombay and para-Bombay phenotypes

Feature Bombay (Oh) Para-Bombay
FUT1 Nonfunctional alleles only Nonfunctional alleles, or a weakly functional allele
FUT2 Nonfunctional alleles only At least one functional allele in most cases
H, A and B antigens on red cells Absent Very weak; H made by the secretor enzyme is adsorbed from plasma
H, A and B substances in saliva Absent Present in secretor individuals
Forward grouping Types as group O; nonreactive with anti-H lectin Weak or apparently absent A or B
Anti-H Present with anti-A and anti-B; causes severe hemolytic transfusion reactions Anti-H, anti-HI or both, usually weak and reacting mainly at 4–22 °C; usually not clinically significant

Sources: Soejima and Koda 2023; Kelly et al. 1994; Subramaniyan 2018.

  • Molecular basis. Inactivating point mutations in both FUT1 alleles define H deficiency in Bombay and para-Bombay pedigrees (Kelly et al. 1994). The ISBT allele table for the H system (v6.1, 2023) listed 77 FUT1 alleles: 2 functional, 37 associated with weak H (para-Bombay) and 38 associated with absent H (Bombay) (Soejima and Koda 2023). The ISBT Blood Group Database has since replaced the PDF allele tables.
  • Frequency. H-deficient phenotypes occur in about 1 in 8,000 people in Taiwan (mainly para-Bombay), 1 in 10,000 in India (mainly Bombay) and 1 in 1,000,000 in Europe (Soejima and Koda 2023).
  • Serologic recognition. The Bombay phenotype was first recognized from anti-H in the serum together with anti-A and anti-B (Soejima and Koda 2023). The plasma agglutinates group O reagent cells, so the antibody screen and every crossmatch with group O units are positive. Among 106 fully investigated ABO discrepancies, 9 were Bombay phenotypes (Desai et al. 2024).
  • Transfusion in the Bombay phenotype. Bombay individuals receive autologous red cells or red cells from other Bombay individuals only (Soejima and Koda 2023).
  • Anti-HI in para-Bombay individuals. Para-Bombay individuals can form anti-H, anti-HI or both, in addition to anti-A and anti-B. Anti-HI does not react with group O cord red cells, which carry H but lack I, and it is not inhibited by group O secretor saliva, which inhibits anti-H. Bombay or para-Bombay red cells are needed when the anti-H or anti-HI is clinically significant, that is, reactive at 37 °C. Anti-HI reacting only at 4 °C is clinically insignificant (Subramaniyan 2018).

ABO subgroups

  • A1 and A2. About 80% of group A individuals express the A1 antigen (Das et al. 2021). A1 red cells carry about four times as many A antigen sites as A2 red cells (Saidin et al. 2026). The A2 red cell carries more H antigen than the A1 red cell (Lahare et al. 2024). Dolichos biflorus lectin (anti-A1) agglutinates A1 red cells and leaves A2 red cells unagglutinated (Lahare et al. 2024).
  • Anti-A1. Naturally occurring IgM anti-A1 is found in 1–8% of A2 individuals and 22–35% of A2B individuals. It reacts best at room temperature or below and is regarded as clinically insignificant (Das et al. 2021). In the reverse grouping it agglutinates A1 reagent cells and produces an apparent group O or group B serum pattern.
  • Weak subgroups. A3, Ax, Am, Ael, B3, Bx, Bm and Bel are weak phenotypes that result from ABO polymorphism, including variants in the promoter and an erythroid regulatory site (Ogasawara et al. 2024).
  • Investigation of a weak A or weak B subgroup (Lahare et al. 2024):
    • strength of agglutination with monoclonal anti-A, anti-A1 (or Dolichos biflorus lectin) and anti-A,B
    • degree of H expression with anti-H or Ulex europaeus lectin
    • anti-A1 in serum
    • A and H substances in saliva
    • adsorption and elution with anti-A
    • family studies and genotyping
Phenotype Molecular basis Typical serology Source
A2 Reduced A antigen with increased H Agglutinated by anti-A; not by anti-A1 lectin; anti-A1 in some sera Das et al. 2021; Lahare et al. 2024; Saidin et al. 2026
A3, B3 Variants in the ABO promoter or erythroid regulatory region Mixed-field agglutination with anti-A or anti-B Ogasawara et al. 2024
Bm Variants in the ABO promoter or erythroid regulatory region Trace B antigen on red cells; near-normal B substance in secretor saliva Ogasawara et al. 2024
cis-AB One allele encodes a transferase with both A and B activity Typically A2B3, with weak, mixed-field B Chun et al. 2019
B(A) Variant B alleles, for example B(A)02, B(A)04 and B(A)05 Normal B with weak A detected by some potent monoclonal anti-A; anti-A in plasma Guo et al. 2007
  • cis-AB. Both A and B antigens are expressed from one allele inherited from one parent. cis-AB is the most frequent weak ABO subgroup in Korea, at 0.0354% of 169,605 Koreans (Chun et al. 2019). An autoanalyzer missed six A2Bw samples, presumed to be cis-AB, that showed 2+ mixed-field reactions with anti-B in tube testing (Lim et al. 2022).
  • B(A). The phenotype is inherited as an autosomal dominant trait. One lot of anti-A can react weakly while another lot is nonreactive (Jain et al. 2017).

Acquired B phenotype

  • Mechanism. Bacterial deacetylases convert the terminal GalNAc of the A antigen into galactosamine, a structure that closely resembles galactose. Some anti-B reagents then react with the group A red cells (Hagman et al. 2024).
  • Clinical setting. The first report (1959) described seven unrelated group A1 patients with a weak B antigen. Their serum contained anti-B, and the saliva of secretors contained only A and H substances. Later cases were elderly patients with carcinoma of the colon or rectum. The change ends when the bacterial infection clears (Hagman et al. 2024).
  • Reagent-dependent detection. A patient with acquired B was mistyped as group AB with the monoclonal anti-B clone ES-4 and died of a hemolytic transfusion reaction after receiving four units of group AB red cells. The clone was withdrawn. Regulatory agencies recommend that new anti-B reagents be nonreactive with acquired B cells, and current monoclonal anti-B reagents generally do not detect acquired B. Acidifying ES-4 to pH 6.0 abolished the reactivity (Hagman et al. 2024).
  • Serologic clues. The B reactivity is weak and confined to particular anti-B clones. The plasma still contains anti-B, and secretor saliva lacks B substance (Hagman et al. 2024).

Classification of ABO discrepancies

A four-group classification sorts discrepancies by cause (Desai et al. 2024). Technical errors are excluded first: improper centrifugation, incorrect cell suspension, missed reagents, misreading and clerical error (Desai et al. 2024).

Group Problem Typical causes Resolution Source
I Weak or missing antibodies in the reverse grouping Age under 4–6 months, older age, hypogammaglobulinemia, recent hematopoietic stem cell transplantation Extended incubation at 4 °C, an altered serum-to-cell ratio, autocontrol and group O cells as controls Desai et al. 2024
II Weak or missing antigens in the forward grouping ABO subgroups, acute leukemia and other myeloid neoplasms Anti-A1 and anti-H lectins, adsorption and elution, saliva testing, genotyping Desai et al. 2024; Lahare et al. 2024
III Protein or plasma abnormalities Rouleaux from abnormal plasma proteins Saline replacement technique Desai et al. 2024
IV Miscellaneous reactivity Bombay phenotype, cold alloantibodies and autoantibodies, mixed warm and cold antibodies Antibody identification; anti-H lectin and saliva studies for a suspected Bombay phenotype Desai et al. 2024
  • Frequency. In 211,568 samples from an oncology center, ABO discrepancies occurred in 0.016% of donor samples and 0.077% of patient samples. Weak or missing antigens predominated in donors. Among patients, 64% of group I cases were in children younger than 1 year, 52% of group II cases had acute leukemia and all 28 group III cases were due to rouleaux (Desai et al. 2024).
  • Mixed-field forward grouping. Two red cell populations give a mixed-field pattern. Causes include A3 and B3 subgroups (Ogasawara et al. 2024), cis-AB (Lim et al. 2022) and chimerism after allogeneic hematopoietic stem cell transplantation. In an ABO-matched transplant recipient, mixed-field ABO typing preceded the change in formal chimerism testing and was the first sign of relapse (Yurtsever et al. 2024).

Workup of an ABO discrepancy

  1. The test is repeated on the same sample, and reagents and equipment are verified.
  2. A new sample is requested when the discrepancy persists.
  3. Previous ABO results and the clinical record (age, diagnosis, transfusion and transplant history, medications) are reviewed.
  4. Additional serologic tests are chosen by group: extended cold incubation, lectins, saline replacement, adsorption and elution, and saliva testing.
  5. Results are recorded, and the final interpretation is deferred until the discrepancy is resolved.
  6. A donor unit with an unresolved discrepancy is quarantined. A recipient with an unresolved discrepancy receives group O red cells.

Source: Desai et al. 2024.

FDA requirements for donor units. Each unit of Whole Blood is classified by ABO group. At least two blood group tests are performed, and the unit is not issued until grouping tests by different methods or with different lots of antisera agree. Only anti-A and anti-B reagents licensed under, or meeting the requirements of, FDA regulations are used, with the technique for which each reagent is designed (21 CFR 640.5(b)). Compatibility-testing regulations and the current AABB Standards edition are covered in Pretransfusion Testing, Antibody Identification, Crossmatch and Drug Interference.

The Rh Blood Group System: D, Weak and Partial D, RhCE Variants and Rh Typing Problems

Definition. The Rh system (ISBT 004) is a protein blood group system encoded by two homologous genes, RHD and RHCE, at 1p36.11 (ISBT Table of blood group systems v12.0). RhD carries the D antigen (RH1). RhCE carries the C, c, E and e antigens (RH2 to RH5) (Wagner and Flegel 2004). The ISBT table (v12.0, 2025) assigns 56 antigens to the system. Rh is the most complex blood group system because of the many variant forms of the D antigen (Wagner and Flegel 2004). Anti-D is the leading cause of hemolytic disease of the fetus and newborn (HDFN) (Clausen and van der Schoot 2025). RhD typing determines both red cell selection and candidacy for Rh immune globulin (RhIG) (Sandler et al. 2015).

Related page: ABO and H Blood Group Systems and ABO Discrepancies (ABO and H systems and ABO discrepancies) Related page: Kell, Duffy, Kidd, MNS, Lewis, I, P1PK and Other Blood Group Systems, Nomenclature and Genotyping (Kell, Duffy, Kidd and genotyping) Related page: Immunohematology Methods in Red Cell Serology (antiglobulin testing, adsorption and elution) Related page: Pretransfusion Testing, Antibody Identification, Crossmatch and Drug Interference (antibody identification and crossmatch) Related page: Blood Component Selection and Serologic Workup of Autoantibodies (RhD selection of components and type switching) Related page: Transfusion Reactions (delayed hemolytic reactions from Rh antibodies)

Structure of the Rh proteins and the RH locus

Feature Finding Source
Proteins RhD and RhCE, each 417 amino acids, with 12 transmembrane segments and 6 extracellular loops Wagner and Flegel 2004
Difference between RhD and RhCE 34–37 amino acids; exofacial differences only in loops 3, 4 and 6 Wagner and Flegel 2004
Genes RHD and RHCE, 10 exons each, opposite orientation, about 30,000 bp apart, with SMP1 between them Wagner and Flegel 2004
Rh complex RhD and RhCE with Rh-associated glycoprotein (RhAG); CD47, LW and glycophorin B are associated Wagner and Flegel 2004; Cartron 1999
RhAG Encoded by RHAG at 6p12.3; ISBT system 030 ISBT table v12.0
Function RhAG and Rh proteins share homology with ammonia transporters and transport ammonia Wagner and Flegel 2004
  • Rhesus boxes. RHD is the duplicated gene. It is flanked by two 9,000-bp segments called Rhesus boxes. Unequal crossing over between them deleted the whole RHD gene in the common D-negative haplotype (Wagner and Flegel 2004).
  • Gene conversion. The similarity and opposite orientation of the two genes favor gene conversion in cis. Parts of one gene are replaced by the corresponding parts of the other, producing RHD-CE-D and RHCE-D-CE hybrid alleles (Wagner and Flegel 2004).

Rh antigens: D, C, c, E, e and G

Antigen Molecular basis Source
D RhD-specific amino acids in exofacial loops 3, 4 or 6 Wagner and Flegel 2004
c Proline at position 103 of RhCE Wagner and Flegel 2004
C RHD-like exon 2 within RHCE, with cysteine at position 16 Wagner and Flegel 2004
E Proline at position 226 Wagner and Flegel 2004
e Alanine at position 226 in an RhCE context Wagner and Flegel 2004
G Serine at position 103, present on RhD and on the C form of RhCE Wagner and Flegel 2004
  • Anti-G. Both D-positive and C-positive haplotypes generally express G, so anti-G reacts with red cells that are D-positive or C-positive (Wagner and Flegel 2004).
  • Haplotypes. Rh haplotypes are written by their antigens, for example DCe, DcE and Dce. Alleles of the Eurasian RHD cluster occur mainly in DCe and DcE haplotypes. Alleles of the African clusters occur mainly in Dce haplotypes (Wagner and Flegel 2004).

Molecular basis of the D-negative phenotype

Mechanism Population Serologic result Source
Deletion of the whole RHD gene The usual cause in Whites; this haplotype makes up 40% of haplotypes in Whites; probably also the most frequent cause in Africans D-negative Wagner and Flegel 2004
RHDΨ pseudogene (37-bp insertion at the intron 3/exon 4 junction and a stop codon in exon 6) About as frequent as the deletion in some African populations D-negative Wagner and Flegel 2004
RHD-CE(4–7)-D hybrid (dCces) Third most common cause of D-negative in Africans; the hybrid protein carries C antigen D-negative, C-positive Wagner and Flegel 2004
RHD-CE(2–9)-D hybrid A major cause in Chinese D-negative Wagner and Flegel 2004
DEL alleles, mainly RHD*DEL1 (RHD*01EL.01, c.1227G>A) About 98% of DEL in East Asians; 30% of D-negative Han Chinese, 28% of D-negative Japanese and 17% of D-negative Koreans; 0.1% of D-negative Whites D-negative by routine methods; anti-D recovered only by adsorption and elution Kwon et al. 2017
  • Prevalence of D-negative. About 14.6% of the racially and ethnically mixed US population is D-negative (Sandler et al. 2015). Among Africans, 3–5% are D-negative (Kwon et al. 2017).
  • Consequence for genotyping. RHD PCR that does not detect RHDΨ gives a false prediction of D-positive in people of African ancestry. Specific detection of RHDΨ is required for D prediction by PCR (Wagner and Flegel 2004).
  • DEL red cells in transfusion. DEL donor units are labeled D-negative and are transfused to D-negative recipients. Case reports from East Asia associate such transfusions with anti-D formation. An estimated 68–683 DEL units from donors of East Asian ancestry are transfused annually as D-negative in the United States (Kwon et al. 2017).
  • DEL individuals as recipients. Among Han Chinese women with a DEL phenotype who delivered a D-positive newborn, none of 130 with RHD*DEL1 formed anti-D. Six women whose DEL resulted from RHD-CE-D hybrid alleles, which lose one or more D epitopes, did form anti-D. In a prospective study, 44 pregnant women with DEL who received no RhIG did not form anti-D (Kwon et al. 2017). Routine serology types these patients as D-negative, and they are managed as D-negative unless genotyped.
  • Donor screening for DEL. DEL is associated with the C antigen. No DEL phenotype was found among D-negative ccee donor samples, and screening apparently D-negative donors for C followed by RHD*DEL1 genotyping has been proposed (Kwon et al. 2017).

Weak D phenotypes

  • Serologic definition. A serologic weak D phenotype is red cell reactivity with anti-D that is absent or weak (2+ or less) on initial testing and moderate or strong in the antiglobulin phase (Sandler et al. 2015).
  • Molecular basis. Most weak D phenotypes result from missense changes in the transmembrane or intracellular segments of RhD. These changes interfere with membrane integration of the protein and have limited effect on the D epitopes (Wagner and Flegel 2004). Weak D types 1, 2 and 3 encode all D epitopes at a lower surface density (Sandler et al. 2015). The weak D types are numbered by molecular structure, and the lowest numbers were given to the most frequent types (Wagner and Flegel 2004).
  • Prevalence. An estimated 0.2–1.0% of Whites inherit an RHD allele that encodes a serologic weak D phenotype. About 95% of Whites in central Europe with a serologic weak D phenotype have weak D type 1, 2 or 3 (Sandler et al. 2015). In a Chicago transfusion service, weak D types 1, 2 and 3 accounted for 66% of serologic weak D phenotypes in White patients and 3% in patients of diverse ethnicity (Barriteau et al. 2022).
  • Alloimmunization risk. Allo-anti-D has not been reported in individuals with weak D type 1, 2 or 3 (Wagner and Flegel 2004; Sandler et al. 2015). Alloimmunization has been observed with weak D type 4.2 (DAR), type 11, type 15, type 21 and type 57. The weak D type 4.2 protein is identical to the partial D DAR (Sandler et al. 2015; Wagner and Flegel 2004).
  • Weak D type 4.0. Sixteen published cases of anti-D in persons with weak D type 4.0 were reviewed by the 2015 Work Group. One was alloanti-D and 15 were autoanti-D. The Work Group did not extend its recommendation to type 4.0 (Sandler et al. 2015).

Partial D phenotypes

  • Definition. A partial D phenotype lacks some D epitopes. Carriers type as D-positive with many reagents but can form anti-D against the missing epitopes (Wagner and Flegel 2004).
  • Hybrid alleles. Replacement of some RhD-specific extracellular loops by RhCE sequence produces the classic partial D categories DIVb, DVa and DVI, and the later-recognized DFR, DHAR and DBT (Wagner and Flegel 2004).
  • Missense partial D. Missense changes in exofacial segments also produce partial D. DNB and DVII are the most important by frequency of anti-D formation (Wagner and Flegel 2004).
  • Low-prevalence antigens. Hybrid proteins create new antigens, for example FPTT in DFR and BARC in DVI (Wagner and Flegel 2004).
  • DVI and reagent design. Fatal HDFN has followed anti-D formed by women with partial DVI. For that reason, monoclonal anti-D reagents licensed in the United States are required to give a negative result with DVI red cells in initial testing. DVI red cells type as D-positive when a weak D test is performed, as in donor testing (Sandler et al. 2015).
Feature Weak D (types 1, 2, 3) Partial D (for example DVI) DEL
Molecular change Missense change inside or below the membrane Hybrid allele or exofacial missense change Splice-site or other change permitting trace expression
Initial direct agglutination Absent or weak (2+ or less) Variable by reagent; DVI negative with US-licensed monoclonal reagents Negative
Antiglobulin-phase weak D test Positive Positive for DVI Negative
Detection Serology and RHD genotyping Monoclonal anti-D panels and RHD genotyping Adsorption and elution, or genotyping
Allo-anti-D after D-positive exposure Not reported Occurs Not observed with RHD*DEL1 (Asia-type DEL); reported with rare hybrid DEL alleles
Management D-positive for transfusion and RhIG D-negative for transfusion and RhIG Donors labeled D-negative by routine serology; patients managed as D-negative unless genotyped

Sources: Sandler et al. 2015; Wagner and Flegel 2004; Kwon et al. 2017; Barriteau et al. 2022.

RhD typing policy and RHD genotyping

Current recommendation (2015 AABB and CAP Work Group). RHD genotyping is recommended when RhD typing results are discordant or a serologic weak D phenotype is detected in a patient, including pregnant women, newborns and transfusion candidates. Persons with weak D type 1, 2 or 3 are managed as D-positive for RhIG and red cell selection. Women with other weak D genotypes receive standard RhIG prophylaxis, including postpartum RhIG when the newborn is D-positive or has a serologic weak D phenotype. Reference laboratories are encouraged to offer tiered RHD genotyping (Sandler et al. 2015).

Previous practice. The 29th edition (2014) still required a weak D method for donors and considered a weak D test unnecessary for recipients, except for red cells of a fetus or newborn of a D-negative mother, to assess the mother's RhIG candidacy. The 22nd edition (2003) stated that a weak D test is not required when a woman's test for D is negative. The 1999 ACOG practice bulletin advised that women with a serologic weak D phenotype be considered D-positive without RhIG. The result was inconsistent RhIG use in women with a serologic weak D phenotype (Sandler et al. 2015). ACOG published Practice Bulletin No. 181 in 2017, and its stated purpose includes new data on women with a weak D phenotype (ACOG 2017). A 2024 ACOG Clinical Practice Update revised the guidance of Practice Bulletin No. 181 on Rh testing and RhIG after abortion or pregnancy loss before 12 weeks of gestation (ACOG 2024).

Current AABB Standards. The notable changes announced for the 35th edition of the AABB Standards for Blood Banks and Transfusion Services (effective April 1, 2026) do not include RhD typing (AABB 2026).

Experience after implementation. In 138 patients with weak or discrepant RhD phenotypes, RHD genotyping found weak D types 1, 2 or 3 in 38%, weak D type 4.0 or 4.3 in 25%, other partial D alleles in 21% and no variant in 15%. Genotyping changed RhD management in 43% of patients and reduced the use of D-negative red cells and RhIG (Barriteau et al. 2022). In that program, partial D genotypes and samples with no variant detected were managed as D-negative (Barriteau et al. 2022).

Fetal RHD genotyping. Fetal RHD genotyping on cell-free DNA from maternal plasma is used as antenatal screening to target RhIG to D-negative pregnant women carrying a D-positive fetus (Clausen and van der Schoot 2025).

Regulatory requirements for RhD typing of donors

  • FDA donor rule. Each unit of Whole Blood is classified by Rh type. A unit positive with anti-D reagent may be labeled Rh positive. A negative result is confirmed by further testing that includes tests for weak D (formerly Du). The unit is labeled Rh negative only if further testing is negative. Units positive on additional, more specific testing are labeled Rh positive (21 CFR 640.5(c)).
  • Licensed reagents. Only anti-Rh blood grouping reagents licensed under, or meeting the requirements of, FDA regulations are used, with the technique for which each reagent is designed (21 CFR 640.5(c)).

RhCE variants and Rh alloimmunization in sickle cell disease

  • Variant RHCE alleles. Many RHCE alleles of African origin differ from the common alleles by several amino acids. Their proteins lack some high-prevalence Rh antigens. For patients with inherited anemias who are immunized to those antigens, compatible blood is difficult to find (Wagner and Flegel 2004).
  • The ce(W16C) allele. This allele, usually in a Dce haplotype, encodes a weakened e antigen. Most African RHCE alleles derive from it (Wagner and Flegel 2004).
  • CE-silent haplotypes. Replacement of all or most RhCE-specific exons by RHD sequence produces D−− (absent C, c, E and e), D·· (with the low-prevalence antigen Evans, RH37) and related phenotypes. These haplotypes are detected only when homozygous or compound heterozygous, and D antigen expression is often enhanced (Wagner and Flegel 2004).
  • Alloimmunization despite matching. In 182 patients with sickle cell disease transfused with D, C, E and K antigen-matched red cells from African American donors, 58% of chronically transfused patients were alloimmunized and 45% were Rh-immunized. Of 146 antibodies, 91 were unexplained Rh antibodies, and one third of these were associated with laboratory evidence of delayed transfusion reactions. Fifty-six antibodies arose in patients whose red cells typed positive for the corresponding antigen. High-resolution RH genotyping found variant alleles in 87% of patients (Chou et al. 2013).
Setting Serologic finding Explanation Source
Patient antigen-positive with an antibody of the same specificity For example, anti-e in an e-positive patient with a negative autocontrol Partial antigen from a variant RHCE allele Chou et al. 2013; Wagner and Flegel 2004
Patient antigen-negative after antigen-matched units New Rh antibody Variant alleles in donor red cells Chou et al. 2013
Antibody to a high-prevalence Rh antigen Reactivity with nearly all panel cells Absence of the antigen from a variant RhCE protein Wagner and Flegel 2004

Rh-null and Rh-mod phenotypes

  • Phenotype. Rh-null red cells lack all Rh antigens. Affected individuals have a clinical syndrome of variable severity with abnormal red cell shape, cation transport and membrane phospholipid organization (Cartron 1999).
  • Regulator type. Regulator-type Rh-null results from homozygosity for a suppressor gene unrelated to the RH locus (Cartron 1999). Mutations in RhAG underlie the regulator form (Wagner and Flegel 2004).
  • Amorph type. Amorph-type Rh-null results from homozygosity for a silent allele at the RH locus. These individuals lack any functional RHCE and RHD gene, usually from RHCE nonsense mutations on a D-negative background (Wagner and Flegel 2004; Cartron 1999).
  • Rh complex model. Rh, RhAG, CD47, LW and glycophorin B form a complex that is not assembled or transported to the cell surface when Rh or RhAG is missing. This explains the loss of LW and the reduction of other complex proteins in Rh-null cells (Cartron 1999).
  • Rh-mod. Variable expression of RHAG alleles may account for Rh-mod, in which Rh antigens are weakly expressed (Cartron 1999).

The LW blood group system

  • Genetics. LW (ISBT 016) is encoded by ICAM4 at 19p13.2 (ISBT table v12.0). It comprises the antithetical antigens LWa and LWb and the high-prevalence antigen LWab (Srivastava et al. 2014). LWEM is a fourth main antigen (Moiz et al. 2025).
  • Relation to D. The ICAM4 protein is part of the Rh complex and is involved in cell adhesion (Srivastava et al. 2014). Anti-LW reacts more strongly with D-positive than with D-negative red cells and can be mistaken for anti-D (Moiz et al. 2025).
  • Distinguishing anti-LW from anti-D. In a D-positive patient with a B-lymphoproliferative disorder, the antibody reacted preferentially with D-positive panel cells. The reactivity was abolished with red cells treated with 0.2 M dithiothreitol (DTT). The plasma reacted strongly with D-positive and D-negative cord red cells and was nonreactive with Rh-null and LW(a−) red cells. The patient tolerated group A, D-negative red cells (Moiz et al. 2025).
  • Acquired LW-negative state. Disease can weaken LW expression and allow anti-LW to form (Moiz et al. 2025).
  • Clinical significance. Anti-LW is not always clinically significant, and LW-negative blood is difficult to find (Crottet 2018).

Sources of RhD typing discrepancies

Cause Pattern Resolution Source
Serologic weak D Equivocal or weak direct reactions; differences between monoclonal reagents RHD genotyping Barriteau et al. 2022; Sandler et al. 2015
Partial D Positive with some monoclonal anti-D and negative with others; anti-D in a D-positive patient RHD genotyping; red cell selection as D-negative Wagner and Flegel 2004; Barriteau et al. 2022
DVI with US-licensed reagents Negative patient typing and positive donor (weak D) typing of the same person RHD genotyping Sandler et al. 2015
DEL D-negative by all routine methods Adsorption and elution, or genotyping Kwon et al. 2017
Recent transfusion Phenotype obscured by donor red cells Genotyping; serologic phenotyping within 3 months of transfusion is unreliable Barriteau et al. 2022
Positive direct antiglobulin test Antiglobulin-phase weak D test cannot be interpreted No valid weak D result Das et al. 2021
Anti-LW Apparent anti-D in a D-positive patient DTT-treated cells, cord cells and Rh-null cells Moiz et al. 2025
Change from historical type Discordance with an earlier typing in another laboratory RHD genotyping Barriteau et al. 2022

Kell, Duffy, Kidd, MNS, Lewis, I, P1PK and Other Blood Group Systems, Nomenclature and Genotyping

Definition. A blood group system is one or more antigens controlled by a single gene locus, or by two or more closely linked homologous genes with little or no observable recombination between them (ISBT terminology). Outside ABO, H and Rh, the systems of greatest clinical importance are Kell, Duffy, Kidd and MNS. After ABO and Rh, antibodies to Kell, Duffy and Kidd antigens remain the most clinically significant (Westhoff and Reid 2004). The carbohydrate systems Lewis, I, P1PK and globoside are clinically relevant mainly through cold-reactive antibodies, autoimmune hemolysis and rare null phenotypes. Several protein systems produce antibodies to high-prevalence antigens that complicate antibody identification.

Related page: ABO and H Blood Group Systems and ABO Discrepancies (ABO, H and secretor status) Related page: The Rh Blood Group System: D, Weak and Partial D, RhCE Variants and Rh Typing Problems (Rh, RhAG and LW) Related page: Immunohematology Methods in Red Cell Serology (enzymes, DTT, adsorption and elution) Related page: Pretransfusion Testing, Antibody Identification, Crossmatch and Drug Interference (antibody identification, high-prevalence antibodies, DTT and daratumumab) Related page: Blood Component Selection and Serologic Workup of Autoantibodies (cold autoantibodies and the positive DAT) Related page: Transfusion Reactions (delayed hemolytic transfusion reaction from Kidd antibodies)

Number of blood group systems recognized by the ISBT

  • Current count. The ISBT Working Party on Red Cell Immunogenetics and Blood Group Terminology lists 49 systems, 57 genes, 400 antigens and 2,031 alleles on its registry page updated 24 September 2026 (ISBT 2026). The 49th system is JAMA (ISBT 049), encoded by F11R on chromosome 1; it carries one high-prevalence antigen, JIMI (049001) (ISBT Blood Group Database 2026).
  • Previous counts. As of June 2024, the ISBT acknowledged 47 systems with 366 antigens, after ratifying ER (ISBT 044), CD36 (045), ATP11C (046) and MAL (047) between December 2021 and June 2024 (Hyland et al. 2026). PIGZ (ISBT 048) was acknowledged at ISBT Milan 2025 (ISBT 2025), which brought the count to 48 systems and 371 antigens (ISBT table v12.0).
  • Recent systems. The ER and MAL systems were established when the genetic basis of the Er and AnWj antigens was identified. CD36 and ATP11C were new entries (Hyland et al. 2026). PIGZ carries the single high-prevalence antigen GWADA. The PIGZ mutation prevents the addition of mannose to a membrane structure, and one GWADA-negative person, from Guadeloupe, is known (ISBT 2025). The ISBT database lists GWADA as provisional (ISBT Blood Group Database 2026).

ISBT blood group nomenclature

Element Convention Example Source
Antigen number Six digits: three for the system and three for the antigen 006003 for Kpa ISBT terminology
System symbol form System symbol plus antigen number; leading zeros may be dropped KEL3 ISBT terminology
Collections 200 series: related antigens that do not meet system criteria Not applicable ISBT terminology
Low-prevalence antigens 700 series: prevalence below 1% and outside any system or collection Not applicable ISBT terminology
High-prevalence antigens 901 series: prevalence above 90% and outside any system or collection Not applicable ISBT terminology
Phenotype System symbol, colon, antigen numbers; a minus sign marks an absent antigen KEL:−1,2,3,4 ISBT terminology
Allele System symbol, asterisk and antigen number, in italics KEL*02 ISBT terminology
Genotype Alleles separated by a slash KEL*02.03/02 ISBT terminology

Summary of the major protein and carbohydrate systems

ISBT no. System Gene Chromosome Carrier molecule or function Source
002 MNS GYPA, GYPB 4q31.21 Glycophorins A and B ISBT table v10.1; Reid 2009
003 P1PK A4GALT 22q13.2 Glycosphingolipids (P1, Pk, NOR) ISBT table v10.1; Hellberg et al. 2013
005 Lutheran BCAM 19q13.2 Lutheran glycoprotein ISBT table v10.1
006 Kell KEL 7q33 Zinc endopeptidase of the neprilysin family ISBT table v10.1; Lee et al. 2000
007 Lewis FUT3 19p13.3 Glycans adsorbed from plasma ISBT table v10.1; Wipplinger et al. 2024
008 Duffy ACKR1 1q21-q22 Atypical chemokine receptor ISBT table v10.1; Meny 2010
009 Kidd SLC14A1 18q11-q12 Urea transporter ISBT table v10.1; Olivès et al. 1995
010 Diego SLC4A1 17q21.31 Band 3 anion exchanger ISBT table v10.1; Figueroa 2013
017 Chido/Rodgers C4A, C4B 6p21.3 Complement C4 ISBT table v10.1; Mougey 2010
019 Kx XK Xp21.1 XK membrane protein linked to Kell ISBT table v10.1; Lee et al. 2000
020 Gerbich GYPC 2q14-q21 Glycophorin C ISBT table v10.1
022 Knops CR1 1q32.2 Complement receptor 1 ISBT table v10.1; Ma et al. 2024
027 I GCNT2 6p24.2 I-branching enzyme ISBT table v10.1; Yu et al. 2001
028 Globoside B3GALNT1 3q25 Globoside (P antigen) ISBT table v10.1
034 Vel SMIM1 1p36.32 Small integral membrane protein 1 ISBT table v10.1; Storry and Peyrard 2017

The Kell and Kx systems

  • Proteins. Kell is a 93-kDa type II glycoprotein of the neprilysin (M13) family of zinc endopeptidases. XK spans the membrane 10 times and carries the single Kx antigen. A disulfide bond between Kell cysteine 72 and XK cysteine 347 links the two proteins (Lee et al. 2000).
  • Antigens. The Kell system had 38 antigens as of January 2025. Twenty-five further alleles encode Kmod phenotypes, and 71 nucleotide changes are associated with the K0 (null) phenotype (Davison and Denomme 2025). K (KEL1) and k (KEL2) are antithetical. The K antigen is present on the red cells of about 9% of Europeans (Ciobanu et al. 2020), so K-negative red cells are readily available.
  • Immunogenicity. The K antigen is second only to D in immunogenicity. Kell alloantibodies cause hemolytic transfusion reactions and HDFN (Denomme 2015). In Swiss hemovigilance data for 2022, anti-Kell antibodies made up 15% of 1,573 reported antibodies, after Rh antibodies at 43% (Mayr et al. 2024).
  • HDFN from anti-K. Anti-Kell antibodies inhibit the growth of Kell-positive erythroid burst-forming and colony-forming units, while anti-D does not. Fetal anemia therefore combines hemolysis with suppressed erythropoiesis, and reticulocytes and normoblasts are inappropriately low (Vaughan et al. 1998). Severe disease occurs despite low amniotic fluid bilirubin and low antibody titers. Late-onset anemia with reticulocytopenia in the infant is attributed to residual antibody (Denomme 2015).
  • Reagent effects. Dithiothreitol (DTT) denatures Kell antigens, and ficin leaves them intact (Chapuy et al. 2015; Manduzio 2024). DTT and ZZAP treatment of red cells is described in Immunohematology Methods in Red Cell Serology.

McLeod phenotype and McLeod syndrome

  • Definition. Absence of the Kx antigen with weak expression of Kell antigens, caused by mutations or deletions of the X-linked XK gene (Ho et al. 1994; Watkins et al. 2011).
  • Clinical features. Acanthocytosis, raised creatine kinase, a Huntington-like chorea, muscle weakness and atrophy, cardiomyopathy and psychiatric disease, usually with onset in the fourth decade (Watkins et al. 2011). The first diagnosis of McLeod syndrome in an infant was reported in 2025 (Davison and Denomme 2025).
  • Contiguous gene deletion. CYBB, the gene for X-linked chronic granulomatous disease, lies near XK at Xp21. A larger deletion removes both genes and produces chronic granulomatous disease with the McLeod phenotype (Watkins et al. 2011).
  • Transfusion. McLeod syndrome may present as hemolytic anemia after transfusion of Kell-positive red cells (Watkins et al. 2011).

The Duffy system

  • Genetics. Duffy was the first blood group mapped to an autosome, chromosome 1. Fya and Fyb are products of the FY*A and FY*B alleles. Fyx, a weak Fyb, results from an additional mutation in FY*B. Fy3, Fy5 and Fy6 are other antigens (Meny 2010).
  • Fy(a−b−) phenotype. Most Duffy-negative individuals of African ancestry carry a silent FY*B allele with a T>C substitution in a GATA-1 binding motif of the promoter, originally reported at nucleotide −46. The mutation abolishes erythroid expression (Tournamille et al. 1995). The glycoprotein is still expressed on nonerythroid cells (Meny 2010). The Fy(a−b−) phenotype is found in about 68% of Black individuals and is uncommon in White and Chinese populations (Makroo et al. 2013). About 60–65% of African Americans carry the Duffy-null genotype, compared with fewer than 1% of persons of European ancestry (Asiimwe et al. 2025).
  • Malaria. Duffy determinants on the red cell surface are required for invasion by Plasmodium vivax merozoites. Fy(a−b−) volunteers exposed to infected mosquitoes were resistant to erythrocytic infection (Miller et al. 1976).
  • Duffy-null associated neutrophil count. The Duffy-null genotype (ACKR1 promoter variant rs2814778, CC) is associated with a lower absolute neutrophil count without increased infection risk. Merz et al. proposed replacing the earlier term benign ethnic neutropenia with Duffy-null associated neutrophil count. In their cohort, 23.8% of healthy Duffy-null adults had an absolute neutrophil count below 2,000/µL (Merz et al. 2023; Asiimwe et al. 2025).
  • Antibodies. Duffy antibodies are usually clinically significant and have caused HDFN (Meny 2010). Anti-Fya is IgG and usually does not bind complement (Manduzio 2024). The effect of ficin on Duffy antigens is listed in Pretransfusion Testing, Antibody Identification, Crossmatch and Drug Interference.

The Kidd system

  • Protein. The Kidd glycoprotein is the erythrocyte urea transporter UT-B, the product of SLC14A1 (Hamilton 2015). Jk(a−b−) red cells lack this protein and have a selective defect of urea transport (Olivès et al. 1995).
  • Antigens. Jka and Jkb differ by c.838G>A (p.Asp280Asn). The ISBT recognizes 23 silencing alleles and 7 alleles producing weak or partial antigens (Hamilton 2015).
  • Null phenotype. Jk(a−b−) occurs in Polynesian and Finnish populations and in persons of African, Indian and Chinese descent (Hamilton 2015). Immunized Jk(a−b−) individuals form anti-Jk3, and compatible donors are rare (Deelert et al. 2010).
  • Urea lysis screen. Jk(a−b−) red cells resist lysis in 2 M urea, while other Kidd phenotypes lyse within minutes. Among 20,163 Thai donors, 5 were Jk(a−b−) by this screen (Deelert et al. 2010).
  • Evanescence and dosage. Kidd antibodies can react with homozygous red cells and fail to react with heterozygous cells (dosage) (Deerej et al. 2026). They often fall below the detection limit weeks to months after immunization, so a negative antibody screen does not exclude prior Kidd sensitization (Furqan et al. 2026; Deerej et al. 2026). Re-exposure causes an anamnestic response and a delayed hemolytic transfusion reaction (Transfusion Reactions). Records of previous antibody identifications are therefore essential before red cell selection (Furqan et al. 2026).

The MNS system

  • Molecular basis. MNS antigens are carried on glycophorin A, glycophorin B and hybrids that arise from single-nucleotide substitution, unequal crossing over or gene conversion. MNS antigens are fully developed at birth (Reid 2009).
  • Clinical significance. Many MNS alloantibodies are not clinically significant. Antibodies to low-prevalence and high-prevalence MNS antigens have caused HDFN (Reid 2009).
  • Anti-M. Anti-M is usually a naturally occurring antibody inactive at 37 °C. An anti-M that reacts at 37 °C and in the antiglobulin phase, with an IgG component, is managed with M-negative, crossmatch-compatible red cells (Tondon et al. 2008). Anti-M shows dosage, reacting more strongly with M+N− than with M+N+ red cells (Manduzio 2024).
  • S−s−U− phenotype. U is present on red cells of almost all Europeans and Asians and absent in about 1% of Black Africans. The S−s−U− phenotype results mainly from two deletions of GYPB of about 110 kb and 103 kb (Gassner et al. 2020).

The Lewis system

  • Adsorbed antigens. Lewis antigens are made by the FUT2 and FUT3 fucosyltransferases mainly in gastrointestinal epithelium. They enter the plasma and are adsorbed onto red cells, which do not synthesize them (Wipplinger et al. 2024).
  • Biosynthesis. Lea is made when FUT3 acts without a functional FUT2 (nonsecretors). Leb is made when both enzymes are active (Wipplinger et al. 2024).
Phenotype Enzyme and secretor status European African Asian
Le(a+b−) Lewis enzyme present; nonsecretor 19–22% 19–23% Less than 1%
Le(a−b+) Lewis enzyme present; secretor 70–72% 52–55% 62%
Le(a−b−) No Lewis enzyme 4–11% 22–29% 11%
Le(a+b+) Lewis enzyme present; weak secretor allele Less than 1% Less than 1% 27%

Source: Wipplinger et al. 2024.

  • Lewis antibodies. Lewis antibodies are predominantly IgM and are not known to cause HDFN (Pourazar 2007). Cord red cells are not agglutinated by anti-Lea or anti-Leb, although Lea can be shown by the indirect antiglobulin test on about half of cord samples (Pourazar 2007). Lewis, I and P1 antigens are minimally expressed on fetal red cells and are not associated with clinically significant fetal hemolysis (Valentini et al. 2025). Group O Le(a+) red cells carry more Lewis antigen than A or B red cells, so Le(a−) red cells are selected for a patient with a potent anti-Lea (Pourazar 2007).
  • Inhibition. Lewis antibodies, like ABH, P1, Sda and Chido/Rodgers antibodies, are inhibited by soluble substances. Inhibition removes one antibody so that other specificities can be identified (Byrne et al. 2019).

The I system and cold agglutinins

  • Biochemistry. The i antigen is a linear repeat of N-acetyllactosamine, and the I antigen is its branched form. The I-branching β-1,6-N-acetylglucosaminyltransferase converts i into I, and GCNT2 encodes this enzyme (Yu et al. 2001).
  • Development. At birth, red cells carry abundant i antigen and almost undetectable I antigen. I increases as i decreases until about 18 months of age, when little i remains (Pourazar 2007). Anti-I therefore agglutinates adult red cells and anti-i agglutinates cord red cells, a pattern used to assign cold agglutinin specificity (Ying et al. 2021).
  • Adult i phenotype. Mutations or deletion of the I-branching enzyme gene cause the adult i phenotype, which is associated with congenital cataracts in Asians (Yu et al. 2001).
  • Prewarm technique. Patient plasma and red cells are warmed separately to 37 °C before they are combined, which minimizes interference from cold-reactive antibodies such as anti-IH (Wongba et al. 2025).
  • Cold agglutinin disease. Most cold agglutinins in primary cold agglutinin disease have I specificity (Berentsen 2016). The direct antiglobulin test pattern and the pretransfusion handling of cold agglutinins are given in Blood Component Selection and Serologic Workup of Autoantibodies. Secondary cold agglutinin syndrome complicates Mycoplasma pneumoniae pneumonia, Epstein-Barr virus infection and aggressive lymphoma (Berentsen 2016). Anti-i is a frequent cold agglutinin in infectious mononucleosis (Rosenfield et al. 1965).

The P1PK and globoside systems

  • Antigens. The P1PK system contains P1, Pk and NOR on glycosphingolipids. The same A4GALT galactosyltransferase synthesizes P1 and Pk, and a polymorphism in an A4GALT exon predicts the P1 and P2 phenotypes. The system was formerly named P (Hellberg et al. 2013). The P antigen (globoside) belongs to the globoside system, encoded by B3GALNT1 (ISBT table v10.1).
  • Anti-P1. Anti-P1 is usually a weak, cold-reactive antibody not implicated in hemolytic transfusion reactions or HDFN (Hellberg et al. 2013).
  • Rare phenotypes. The p, P1k and P2k phenotypes are associated with a higher frequency of miscarriage (Hellberg et al. 2013). Individuals with the p phenotype form anti-PP1Pk, which causes severe hemolytic transfusion reactions, recurrent spontaneous abortion and HDFN (Di Ciaccio et al. 2021).
  • Pathogen receptors. Globoside (P antigen) is the cellular receptor for parvovirus B19, and red cells lacking P are not agglutinated by the virus (Brown et al. 1993).
  • Paroxysmal cold hemoglobinuria. Most Donath-Landsteiner antibodies with reported specificity are IgG anti-P (Jacobs et al. 2023). The Donath-Landsteiner test and the workup are given in Blood Component Selection and Serologic Workup of Autoantibodies.

Lutheran, Diego and other protein systems

System Features Source
Lutheran Variants in the erythroid transcription factor KLF1 reduce expression of Lutheran and Indian antigens (In(Lu) phenotype). Transfusion requirements of In(Lu) individuals differ from those of the true Lu-null phenotype Fraser et al. 2019
Diego Carried on band 3 (anion exchanger 1). Of 22 antigens recognized in 2013, 3 are of high prevalence. Anti-Dia, anti-Dib, anti-Wra, anti-ELO and anti-DISK are the clinically significant antibodies Figueroa 2013
Chido/Rodgers Ch and Rg are epitopes on complement C4. Anti-Ch and anti-Rg are identified by neutralization with Ch-positive or Rg-positive plasma Mougey 2010
Knops Antigens on complement receptor 1. Anti-Knops antibodies are common and usually not clinically significant. The Helgeson phenotype has about 10% of normal CR1 and a frequency of 1% Ma et al. 2024
Vel SMIM1 carries Vel; Vel− red cells are homozygous for a SMIM1 deletion. Anti-Vel readily hemolyzes Vel+ red cells and has caused severe transfusion reactions Storry and Peyrard 2017
Gerbich Carried on glycophorin C. Anti-Ge2 has caused transfusion reactions ISBT table v12.0; Crottet 2018
Colton Carried on aquaporin 1; Colton antigens are normal on Jk(a−b−) red cells ISBT table v12.0; Olivès et al. 1995
  • High-titer, low-avidity antibodies. The term HTLA describes a heterogeneous group of antibodies, typified by anti-Kna, with weak antiglobulin-phase reactivity (Ma et al. 2024). Inhibition with recombinant soluble CR1 identifies Knops antibodies (Byrne et al. 2019).
  • Clinical significance of rare antibodies. For antibodies to high-prevalence antigens, the monocyte monolayer assay helps decide whether antigen-negative blood is required (Crottet 2018).

Blood group genotyping

  • Basis. Many blood group antigens result from single-nucleotide variants, for example K and k (Lee et al. 2000) and Jka and Jkb (Hamilton 2015). DNA-based assays therefore predict the red cell phenotype.
  • FDA-approved platform. The Immucor PreciseType Human Erythrocyte Antigen (HEA) Molecular BeadChip Test was approved on May 21, 2014 (PMA BP130026) for molecular determination of allelic variants that predict erythrocyte antigen phenotypes (FDA 2014).
  • Recently transfused patients. Donor red cells obscure serologic phenotyping for about 3 months after transfusion, while genotyping uses the patient's leukocyte DNA (Barriteau et al. 2022).
  • Sickle cell disease. High-resolution RH genotyping explains Rh antibodies that form despite serologic matching (The Rh Blood Group System: D, Weak and Partial D, RhCE Variants and Rh Typing Problems).
  • Null and silent alleles. Genotyping that does not detect silencing variants mispredicts the phenotype. Examples are RHDΨ (Wagner and Flegel 2004), the FY GATA promoter variant (Tournamille et al. 1995) and GYPB deletions in the S−s−U− phenotype (Gassner et al. 2020).
  • Noninvasive fetal genotyping. Cell-free DNA from maternal plasma predicts fetal antigens in immunized pregnancies to assess the risk of HDFN (Clausen and van der Schoot 2025). Fetal RHD screening for RhIG prophylaxis is described in The Rh Blood Group System: D, Weak and Partial D, RhCE Variants and Rh Typing Problems.
  • Rare donors. SMIM1 genotyping allows universal screening for Vel− donors (Storry and Peyrard 2017). The urea lysis screen, confirmed by antiglobulin testing, identifies Jk(a−b−) donors (Deelert et al. 2010).

Immunohematology Methods in Red Cell Serology

Definition. Immunohematology methods are the serologic techniques that detect binding of antibody to red cell antigens. Their visible endpoint is agglutination, hemolysis or adherence of red cells. These methods are used in ABO and RhD typing, antibody detection and identification, crossmatching, antibody titration and the workup of a positive direct antiglobulin test (DAT). In the United States the reagents are licensed under 21 CFR Part 660, and laboratory quality control follows the Clinical Laboratory Improvement Amendments (CLIA) regulations in 42 CFR Part 493.

Related page: Pretransfusion Testing, Antibody Identification, Crossmatch and Drug Interference (type and screen, panel interpretation, crossmatch and drug interference) Related page: Blood Component Selection and Serologic Workup of Autoantibodies (component selection and the workup of autoantibodies and a positive DAT) Related page: ABO and H Blood Group Systems and ABO Discrepancies (ABO typing and ABO discrepancies) Related page: The Rh Blood Group System: D, Weak and Partial D, RhCE Variants and Rh Typing Problems (RhD typing and weak and partial D) Related page: Kell, Duffy, Kidd, MNS, Lewis, I, P1PK and Other Blood Group Systems, Nomenclature and Genotyping (antigen properties by blood group system) Related page: Transfusion Reactions (laboratory investigation of transfusion reactions)

Antigen-antibody reactions in red cell serology

  • Two stages of agglutination. In the first, nonvisible stage (sensitization), antibody binds to antigen on the red cell membrane. In the second, visible stage, sensitized cells collide and are linked into agglutinates (Fernandes 2011).
  • Zeta potential. The carboxyl groups of sialic acid give red cells a negative surface charge, which creates a repulsive zeta potential between cells. In isotonic saline, two red cells cannot approach closer than 50–100 Å. IgM agglutinates red cells in saline, whereas the shorter IgG molecule sensitizes them without agglutination (Fernandes 2011).
  • IgM antibodies agglutinate red cells directly. IgG antibodies sensitize red cells, and the sensitization is detected with antihuman globulin (AHG) (Manduzio 2024).
  • Naturally occurring antibodies such as anti-A and anti-B are mainly IgM. Immune antibodies such as anti-D and anti-Fya are usually IgG (Manduzio 2024).
  • Phase of reactivity predicts clinical significance. Reactivity at 37 °C or in the antiglobulin phase suggests a clinically significant IgG antibody. Reactivity only at room temperature suggests an IgM antibody of little clinical relevance (Manduzio 2024).
  • Reduction of IgM. Dithiothreitol (DTT) breaks the disulfide bonds that hold IgM in pentameric form (Bub 2017). DTT treatment of plasma removes IgM activity, so the residual reactivity is IgG (Datta 2021).

Hemagglutination test platforms

Four platforms are in use. The tube test remains the reference method (Bajpai 2012).

Platform Principle Positive reaction Negative reaction Practical features
Tube test Red cells and plasma are mixed, incubated if required and centrifuged; the antiglobulin phase follows saline washes Agglutinates after resuspension Smooth suspension Reference method. Washing can elute low-affinity antibody, and reading varies between observers (Bajpai 2012)
Column agglutination (gel or glass bead) A 0.8–1% red cell suspension and plasma are centrifuged through a matrix that may contain AHG or a typing antiserum (Bajpai 2012) Cells trapped in the matrix (Lapierre 1990) Cells form a button at the bottom (Lapierre 1990) The antiglobulin test needs no washing. Reactions remain readable for hours (Lapierre 1990) and up to 24 h on the card (Bajpai 2012)
Solid-phase red cell adherence Antigen or antibody is bound to a microplate well; anti-IgG-coated indicator cells detect bound IgG (Bajpai 2012) Cells spread over the well (Bajpai 2012) Cells form a central button (Bajpai 2012) Sensitivity exceeds the tube test and is comparable to column agglutination (Bajpai 2012)
Erythrocyte-magnetized technology Paramagnetic particles adsorbed onto red cells replace centrifugation (Bajpai 2012) Agglutinated cells form a button Free cells resuspend on shaking Published performance data are limited (Bajpai 2012)
  • Grading in column agglutination. Reactions are graded 0 (negative), 1+, 2+, 3+ and 4+, with a separate mixed-field reading. A 0 reaction is a well-defined button of unagglutinated cells at the bottom of the microtube. A 4+ reaction is a solid band of agglutinates on top of the gel. Mixed field is agglutinates at the top of or throughout the gel together with a button of unagglutinated cells (Ortho anti-K instructions for use). A card reader adds objectivity to grading (Bajpai 2012).
  • Grading in tube tests. A 4+ reaction is one solid agglutinate, 3+ several large agglutinates, 2+ medium-sized agglutinates with a clear background and 1+ small agglutinates with a turbid background (Routray 2024).
  • Reading tube tests. Excessive agitation during resuspension can disrupt weak agglutination and produce a false-negative result (Alba Bioscience anti-IgG package insert).

Enhancement media in antibody detection

Enhancement media shorten incubation or increase the strength of weak reactions.

Medium Description Effect on testing Source
Low-ionic-strength saline (LISS) Introduced by Löw and Messeter in 1974; now supplied mainly as additive solutions. Fewer free Na+ and Cl− ions reduce the ionic layer around the red cell, which raises the rate of antibody association (Fernandes 2011) Shortens incubation and keeps the sensitivity and specificity of the antiglobulin test. Detects alloantibodies of all major blood groups in screening, identification and crossmatching Löw 1974; Walker 2018; Fernandes 2011
Polyethylene glycol (PEG) Water-soluble polymer that removes water from the red cell surroundings (Fernandes 2011). 20% PEG of molecular weight 4,000 Da was optimal in the original study Of 25 weak antibodies, 64% reacted most strongly in PEG, 28% equally and 8% more weakly than in Polybrene or LISS. The false-positive rate with anti-IgG was 1.5%. PEG detected specific antibodies in 2 of 24 hemolytic transfusion reactions with no antibody by routine methods Nance 1987; Fernandes 2011
Proteolytic enzymes (ficin, papain) Applied to reagent cells in one-stage or two-stage procedures. They reduce the negative charge of red cells (Fernandes 2011) Enhance Rh, P1, I, Kidd and Lewis antibodies. Destroy M, N and Duffy antigens. Kell is unaffected by ficin. S and s are variably affected Manduzio 2024; Bruce 2022; Fernandes 2011
  • Uses of enzyme-treated cells. They separate multiple antibodies, enhance detection of weak antibodies and improve adsorption. Quality control confirms adequate treatment before further testing (Bruce 2022).
  • Incubation. Tube antiglobulin tests are incubated at 37 °C for 30–60 minutes without a potentiator, or as the potentiator manufacturer specifies (Alba Bioscience anti-IgG package insert).

Antiglobulin test principles

The antiglobulin test was introduced by Coombs, Mourant and Race in 1945 to detect weak and "incomplete" Rh antibodies (Coombs 1945).

  • Direct antiglobulin test (DAT). It detects IgG or complement bound to the patient's red cells. AHG is added without incubation or potentiator (Manduzio 2024).
  • Indirect antiglobulin test (IAT). Plasma is incubated with reagent or donor red cells at 37 °C. The cells are washed, and bound IgG is detected with AHG (Alba Bioscience anti-IgG package insert). Antibody screening, antibody identification panels and the AHG crossmatch are IAT-based tests (AABB Association Bulletin #16-02).
  • Autocontrol. The patient's plasma is tested against the patient's own red cells with a potentiator and incubation. A positive autocontrol with a negative DAT indicates a possible false-positive result (Manduzio 2024).

Regulatory classes of antihuman globulin reagents

Reagent class (21 CFR 660.55) Content
Anti-IgG, -C3d; polyspecific Anti-IgG and anti-C3d; may contain other anticomplement and anti-immunoglobulin antibodies
Anti-IgG No anticomplement activity
Anti-IgG; heavy chains Reacts only with human gamma chains
Anti-C3b, anti-C3d, anti-C4b, anti-C4d One complement specificity each; no anti-immunoglobulin activity
  • Licensing requirements. Potency tests measure anti-IgG and anticomplement activity (21 CFR 660.54). Polyspecific and anti-IgG reagents may be colored green (21 CFR 660.51). Complement-sensitized red cells used in testing are checked with positive and negative control antisera (21 CFR 660.53).

Washing and antiglobulin control cells in tube tests

  • Washing. The tube test is washed 3–4 times with a large excess of isotonic saline. Residual saline left after washing dilutes the AHG below its working concentration (Alba Bioscience anti-IgG package insert).
  • Residual plasma. Small amounts of residual patient plasma neutralize anti-IgG, and insufficient or inappropriate washing can lead to false-negative or false-positive reactions (Biotest/Olympus Anti-IgG Solidscreen II package insert).
  • Control cells. IgG-sensitized red cells are added to every negative tube antiglobulin test (Alba Bioscience anti-IgG package insert). Agglutination of the control cells confirms active anti-IgG. Absence of agglutination indicates neutralized or omitted reagent. The test is then invalid and is repeated (American Red Cross anti-k package insert).
  • Column methods. The antiglobulin test in column agglutination requires no washing (Lapierre 1990).

Antibody titration

Titration estimates the amount of antibody by testing serial dilutions of plasma.

  • Method. Plasma is diluted in serial doubling steps in saline from neat to 1:1024 or 1:2048. The titer is the reciprocal of the highest dilution that gives 1+ agglutination (Aldarweesh 2026).
  • Method dependence. In a 2026 multicenter study, automated gel titers of anti-D were 2.5–3 dilutions higher than saline tube IAT titers. The difference narrowed at high titers. A tube titer of 8 corresponded to gel titers of 32–64, and a tube titer of 16 to gel titers of 64–128 (Aldarweesh 2026). A Finnish study of 147 antenatal samples with clinically significant antibodies found gel titers a mean 2.88 dilutions above tube titers. It proposed a gel critical titer of ≥64 for high-risk assessment, against a tube critical titer of ≥16 (Sulin 2025).
  • Prenatal thresholds. ACOG and AABB recommend a critical anti-D titer between 8 and 32 to select pregnancies for more intensive monitoring for hemolytic disease of the fetus and newborn (Yazer 2024). One maternity hospital used a critical titer of ≥16 (Yazer 2024). A fourfold (two-dilution) rise in titer is a concern to obstetricians (Aldarweesh 2026).
  • ABO titration. Anti-A and anti-B titers guide treatment in ABO-incompatible stem cell and solid-organ transplantation. Immediate-spin titers exceeded AHG titers in group A and group B donors, and agreement between tube and column methods by AHG was poor. DTT pretreatment lowers AHG titers by removing IgM (Datta 2021).
  • Quality control of titration. The 14th edition of the AABB Standards for Immunohematology Reference Laboratories took effect on April 1, 2026. It requires a defined process to detect titration errors, with appropriate controls on each day titration is performed. AABB lists this requirement among the notable changes from the previous edition (AABB 2026). The 14th edition replaced the 13th edition, which took effect on April 1, 2024 (AABB 2024).

Adsorption techniques

Adsorption removes an antibody from plasma by incubation with red cells that carry the antigen. The adsorbed plasma is then tested for antibodies that remain.

Technique Adsorbing cells Main use Limitation or performance Source
Autologous adsorption Patient's own red cells Removal of warm autoantibody to reveal alloantibodies Not used when the patient has been transfused in the previous 3 months. Transfused antigen-positive red cells still in the circulation adsorb alloantibody: in vitro, 2–6% antigen-positive cells removed all anti-D, -E and -Fya reactivity Laine 2000; Kokoris 2022
Allogeneic adsorption Most often a trio of phenotyped reagent red cells, untreated or treated with enzyme or ZZAP; LISS or PEG may be added Removal of warm autoantibody in recently transfused patients; separation of multiple alloantibodies Several rounds may be needed. Alloantibodies to high-prevalence antigens are not detected Barron 2014; Ekema 2017
PEG adsorption Allogeneic red cells in the presence of PEG Removal of warm autoantibody All 16 alloantibodies in 39 sera reacted at least as strongly as after ZZAP adsorption. Adsorption time fell from 30.5 h to 13.75 h Leger 1999
Rabbit red cell adsorption Rabbit red cells or stroma Removal of cold autoagglutinins Can also remove alloantibodies to antigens present on rabbit red cells Cobaugh 2018
  • Frequency of underlying alloantibodies. Underlying alloantibodies are found in about 30–40% of patients with panreactive warm autoantibodies: 39 of 126 (31%) in one series (Maley 2005) and 117 of 309 (38%) in another (Wilson 2019).
  • Dilution as an alternative to adsorption. Testing a 1-in-5 dilution of plasma missed 27% of clinically significant alloantibodies. Only 22% of warm autoantibodies without alloantibodies became nonreactive (Leger 1999).
  • Misuse of prewarming and cold adsorption. In one reported case, rabbit cell and cold allogeneic adsorption reduced reactivity that was in fact anti-Vel, and a prewarmed IAT made the antibody appear nonreactive and masked its in vitro hemolysis. Anti-Vel hemolyzed red cells in vitro in LISS and with papain-treated cells. EDTA-treated serum, which prevents complement-mediated hemolysis, gave 3+ agglutination with Vel-positive cells and none with 10 Vel-negative cells. The patient died 6–8 hours after transfusion of 2 units of washed red cells (Storry 1994).

Elution techniques

Elution dissociates antibody from coated red cells into an inert diluent. The resulting eluate is tested to identify the antibody that coats the cells of a patient with a positive DAT (Hinrichs 2014).

Elution method Main use Source
Acid elution, including cold acid kits Recovery of IgG alloantibodies and warm autoantibodies in most cases Hinrichs 2014
Heat elution (modified Landsteiner-Miller) ABO hemolytic disease of the fetus and newborn; detection of weak A and B antigens by adsorption-elution; removal of interfering IgM agglutinins Dean-El 2019
Xylene, chloroform, digitonin acid, dichloromethane, citric acid Alternatives to acid elution; compared with cold acid elution Hinrichs 2014
  • Eluates when the DAT shows complement only. Acid elution recovers IgG, so an eluate from cells coated with C3 alone is expected to be nonreactive. In 321 such eluates from a reference laboratory, the eluate was most often nonreactive. Alloantibodies were found in 6% and panagglutination in 22%. Only 9% were informative. Elution is therefore reserved for selected cases, guided by recent transfusion, active hemolysis and serum autoreactivity (Meyer 2025).

Dithiothreitol and ZZAP treatment of red cells

  • DTT. DTT denatures or modifies antigens of the Kell, Lutheran, YT, JMH, LW, Cromer, Indian, Dombrock and Knops systems. It also destroys CD38 on red cells (Bub 2017).
  • Uses of DTT-treated cells. They remove interference by therapeutic anti-CD38 antibodies (Chapuy 2015). They also disperse spontaneous agglutination of red cells heavily coated with IgM autoantibody, which otherwise invalidates ABO/RhD typing and the DAT (Bub 2017).
  • ZZAP. ZZAP is 0.1 M DTT combined with 0.1% cysteine-activated papain. It removes IgG from red cells with a positive DAT, which neither chemical achieves alone. It denatures Kell, Duffy and MNSs antigens and leaves ABH, Rh and Kidd antigens intact. ZZAP-treated cells are used in warm autoadsorption, and ZZAP-treated autologous red cells can be typed for Rh and Kidd antigens (Branch 1982).

Reagent quality control in immunohematology

Requirement Source
Each qualitative procedure includes a positive and a negative control at least once each day patient specimens are tested 42 CFR 493.1256(d)(3)(ii)
Each batch, lot or shipment of reagents and antisera is checked for positive and negative reactivity when prepared or opened 42 CFR 493.1256(e)(1)
All immunohematology control procedures are documented 42 CFR 493.1271(f)
Pooled screening cells combine cells from no more than two donors 21 CFR 660.34(b)
Labeling of reagent red cells states that reactivity can decrease during the dating period 21 CFR 660.35(a)(8)

Screening cell antigen requirements and screen sensitivity are covered in Pretransfusion Testing, Antibody Identification, Crossmatch and Drug Interference.

Automated immunohematology

  • Platforms. Automated analyzers based on column agglutination (Dara 2019) and on solid-phase red cell adherence (Harach 2018) are in use.
  • Advantages. Automation reduces errors in sample identification, testing, interpretation and transcription. It improves traceability of samples, reagents and staff, and shortens turnaround time in high-throughput settings (Bajpai 2012).
  • Limitations. Semi-automated systems retain manual steps in labeling, dilution and reagent addition. Systems without a laboratory information system interface keep a risk of transcription error. Initial cost and specimen requirements are higher (Bajpai 2012).

Pretransfusion Testing, Antibody Identification, Crossmatch and Drug Interference

Definition. Pretransfusion testing is the set of procedures that establishes the compatibility of a donor's blood or blood component with a potential recipient (21 CFR 606.3(j), as cited in FDA 2011). It comprises positive identification and collection of the recipient sample, ABO and RhD typing, a test for unexpected red cell antibodies, identification of any antibody found and a crossmatch. The crossmatch is serologic or computerized (FDA 2011). The aim is to prevent hemolytic transfusion reactions. The most common cause of severe acute hemolytic reactions is ABO-incompatible transfusion after an identification error (Transfusion Reactions).

Related page: Immunohematology Methods in Red Cell Serology (test platforms, enhancement media, antiglobulin test, adsorption and elution) Related page: Blood Component Selection and Serologic Workup of Autoantibodies (component selection, emergency release and autoantibody workup) Related page: ABO and H Blood Group Systems and ABO Discrepancies (ABO discrepancies) Related page: The Rh Blood Group System: D, Weak and Partial D, RhCE Variants and Rh Typing Problems (RhD typing problems) Related page: Kell, Duffy, Kidd, MNS, Lewis, I, P1PK and Other Blood Group Systems, Nomenclature and Genotyping (antigen and antibody properties by system) Related page: Transfusion Reactions (hemolytic transfusion reactions)

Regulatory framework for compatibility testing in the United States

Requirement Content Source
Recipient sample identification Standard operating procedures include a method of collecting and identifying recipient samples that ensures positive identification 21 CFR 606.151(a)
Sample age Fresh serum or plasma less than 3 days old is used for all pretransfusion testing if the recipient was pregnant or transfused within the previous 3 months 21 CFR 606.151(b)
Demonstration of incompatibility Procedures demonstrate incompatibility between the donor's cell type and the recipient's serum or plasma type 21 CFR 606.151(c)
Minor crossmatch Required only when the donor unit was not tested by a method that detects agglutinating, coating and hemolytic antibodies 21 CFR 606.151(d)
Laboratory testing ABO grouping, RhD typing, antibody detection, antibody identification and compatibility testing follow the manufacturer's instructions and 21 CFR 606.151(a)–(e) 42 CFR 493.1271(a)
Accreditation standards AABB Standards for Blood Banks and Transfusion Services, 35th edition, effective April 1, 2026; replaced the 34th edition (2024) AABB 2026; Circular of Information 2024
  • Change in the federal rule in 2001. Before September 5, 2001, 21 CFR 606.151 required a major crossmatch of donor cells with recipient serum by a method that included the antiglobulin test. A computer crossmatch was allowed only with written FDA approval. The amended rule requires procedures that demonstrate incompatibility, and a validated computer crossmatch meets it (FDA 2011).
  • Sample age before 2001. The earlier rule required recipient serum less than 48 hours old for all pretransfusion testing. The 2001 amendment set the current rule: a sample less than 3 days old when the patient was pregnant or transfused within the previous 3 months (21 CFR 606.151(b), April 1, 1999 edition; FDA 2011).

Recipient sample identification and sample age

  • Identification at collection. The sample drawn for testing is identified at collection by the method required in 21 CFR 606.151(a). Bedside identification at transfusion is covered in Blood Component Selection and Serologic Workup of Autoantibodies.
  • Counting sample age. The day of collection is day 0, and the sample expires at midnight on day 3 (FDA 2011).
  • Wrong blood in tube. "Wrong blood in tube" is the major cause of ABO errors. A second ABO/RhD determination is therefore made on a separately drawn specimen, or a record of a previous determination is used. Repeat testing of the same specimen is not recommended. In emergencies with only one specimen, the repeat test is performed by a different technologist or with different reagents (FDA 2011).
  • Group O when the type is unconfirmed. In the original computer crossmatch procedure, group O red cells were issued until two concordant ABO types were on record, one from a current sample (Butch 1994).

ABO and RhD typing and the antibody screen

  • ABO grouping. Red cells are tested with at least anti-A and anti-B. The serum is tested with A1 and B red cells to confirm the group. RhD typing uses anti-D (42 CFR 493.1271(a)).
  • Screening cells. Group O reagent red cells for antibody detection carry D, C, E, c, e, K, k, Fya, Fyb, Jka, Jkb, Lea, Leb, P1, M, N, S and s (21 CFR 660.33). Pooled screening cells are not recommended for pretransfusion tests that replace a major crossmatch (21 CFR 660.35(a)(4)).
  • Sensitivity of the screen. When no antiglobulin crossmatch is performed, the safety of compatibility testing depends on correct ABO/RhD typing and the antibody screen. Screening cells with homozygous expression of clinically significant antigens and potentiators help ensure adequate sensitivity (FDA 2011).
  • Type and screen. A sample with a valid ABO/RhD type and a negative antibody screen allows red cells to be issued after an immediate-spin or computer crossmatch (FDA 2011; Butch 1994).

Antibody identification on a reagent red cell panel

A positive screen is followed by testing against a panel of group O reagent red cells of known phenotype.

  1. Phase and strength. The phase and strength of reactivity with each cell are recorded and interpreted as described in Immunohematology Methods in Red Cell Serology (Manduzio 2024).
  2. Exclusion. An antibody is excluded when a nonreactive cell carries the antigen. For antigens that show dosage (Rh other than D, Kidd, Duffy, MNS), exclusion uses cells with homozygous expression. Laboratories differ in the number required: some accept one nonreactive homozygous cell (LearnSerology), and others require two (Manduzio 2024). Anti-K is excluded by one nonreactive homozygous cell or two nonreactive heterozygous cells (Manduzio 2024; LearnSerology).
  3. Dosage. Antibodies of the Rh (except D), Kidd, Duffy and MNS systems react more strongly with homozygous cells. Exclusion with heterozygous cells is therefore unreliable for these antibodies (Manduzio 2024).
  4. Rule of three. A specificity is assigned when at least three antigen-positive cells react and three antigen-negative cells do not react (Manduzio 2024). Three reactive antigen-positive and three nonreactive antigen-negative cells correspond to a probability of 1 in 20 (P = 0.05, Fisher exact test) that the pattern arose by chance (Harris 1986; Kanter 1997).
  5. Patient phenotype. The patient's red cells lack the corresponding antigen (Manduzio 2024).
  6. Autocontrol and direct antiglobulin test (DAT). A negative autocontrol makes autoantibody, drug interaction and sensitized transfused cells unlikely (Manduzio 2024).
Specificity Effect of ficin Dosage Clinical note Source
Rh antibodies (anti-C, -c, -E, -e) Enhanced reactivity Yes Mostly IgG; bind at 37 °C in the IAT Manduzio 2024
Anti-Fya, anti-Fyb Antigen destroyed Yes Anti-Fya is usually an immune IgG antibody Manduzio 2024
Anti-Jka, anti-Jkb Enhanced reactivity Yes Anti-Jka has caused delayed hemolytic transfusion reactions Manduzio 2024; Furqan 2026; Salarvand 2025
Anti-M, anti-N Antigen destroyed Yes Anti-M usually cold-reacting and clinically insignificant Manduzio 2024
Anti-S, anti-s Variable Yes Anti-s is a clinically significant IgG Manduzio 2024
Anti-K Unaffected Excluded by one nonreactive homozygous cell or two nonreactive heterozygous cells Anti-K can cause severe transfusion reactions and hemolytic disease of the fetus and newborn Manduzio 2024; American Red Cross anti-k package insert

Multiple antibodies and panreactive plasma

  • Methods to separate antibodies. They include neutralization of plasma, titration, elution, chemical or enzyme treatment of reagent cells and adsorption with allogeneic red cells (Ekema 2017).
  • Neutralization (inhibition). Some antibodies are inhibited by soluble antigen, which removes their reactivity and reveals other antibodies in the same plasma. Anti-Lea and anti-Leb are inhibited by saliva from secretors. Anti-P1 is inhibited by hydatid cyst fluid or pigeon egg albumin. Anti-Sda is inhibited by human urine or saliva and by guinea pig urine. Anti-Ch and anti-Rg are inhibited by pooled plasma. A dilution control with an inert substance is tested in parallel (Byrne 2019).
  • Sda nomenclature. Sda was a 901-series high-prevalence antigen. It is now the antigen of the SID blood group system, ISBT number 038 (Stenfelt 2023).
  • Approach to panagglutination. The workup begins with the intensity of reactivity with the reagent cells and the result of the autocontrol (Kokoris 2022). It then uses the patient's antigen phenotype, enzyme-treated and homozygous cells, adsorption and elution, and plasma inhibition for anti-Ch and anti-Rg (Kokoris 2022).
Cause of panreactive plasma Distinguishing findings Source
Warm autoantibody DAT positive for IgG, or IgG and complement; underlying alloantibodies are common (Immunohematology Methods in Red Cell Serology) Datta 2024
Anti-CD38 therapy Reactive with all cells in every medium, usually 1+; nonreactive with DTT-treated cells AABB Association Bulletin #16-02; Chapuy 2015
Anti-CD47 therapy 2+ to 3+ in manual gel cards and 4+ in automated analyzers, with carryover between samples; resolved in vitro by a neutralizing reagent Yoon 2024
Antibody to a high-prevalence antigen Similar strength with all panel cells and a negative autocontrol; not detected by allogeneic adsorption Kokoris 2022; Barron 2014
Reagent-related reactivity Resolves with a change of enhancement medium or reagent supplier, washing of the test cells or another antiglobulin reagent Kokoris 2022
  • Dithiothreitol (DTT)-treated panel cells. A panel with DTT-treated cells helps identify antibodies to DTT-sensitive antigens, which are listed in Immunohematology Methods in Red Cell Serology (Bub 2017). A hemolytic anti-Vel masked by prewarming is described there as well.

Interference by therapeutic monoclonal antibodies

Anti-CD38 antibodies (daratumumab and isatuximab) bind CD38 on reagent red cells and cause panreactivity in vitro (Chapuy 2015; AABB Association Bulletin #16-02).

Test Effect of anti-CD38 Source
ABO/RhD typing No interference AABB Association Bulletin #16-02
Immediate-spin crossmatch No interference AABB Association Bulletin #16-02
Antibody screen and panel (indirect antiglobulin test, IAT) Reactive with all cells in every medium (saline, LISS, PEG) and every method (tube, gel, solid phase); usually 1+, up to 4+ in solid phase AABB Association Bulletin #16-02
Antiglobulin crossmatch Incompatible; compatible when DTT-treated donor cells are used AABB Association Bulletin #16-02
DAT and autocontrol May be positive for IgG AABB Association Bulletin #16-02
Dominant Lu(a−b−) cells Can be nonreactive, which mimics a Lutheran-related antibody AABB Association Bulletin #16-02
  • Resolution with DTT. DTT treatment of CD38-positive HL60 cells reduced daratumumab binding by 92% (Chapuy 2015). DTT also destroys Kell antigens. K-negative units are therefore provided unless the patient is known to be K-positive (AABB Association Bulletin #16-02).
  • Antibodies missed with DTT-treated cells. Anti-k, anti-Yta, anti-Doa and anti-Dob are not detected with DTT-treated screening cells (AABB Association Bulletin #16-02).
  • Other mitigation methods. Cord red cells lack CD38. Recombinant anti-daratumumab idiotype reagents (daratumumab only) succeed in 93% of samples. Soluble CD38 and Fab fragment reagents neutralize or mask the interference. Trypsin treatment of reagent cells succeeds in 98.4%. Adsorption with untreated or ZZAP-treated cells fails (AABB Association Bulletin #16-02).
  • Duration. Positive IATs persist for up to 6 months after anti-CD38 is stopped (AABB Association Bulletin #16-02).
  • Baseline testing. A baseline type and screen is performed before therapy starts. The March 2026 update states that a baseline phenotype or genotype may be considered and that genotyping can follow the start of therapy. The earlier versions (January 2016, updated April 2023) stated that a baseline phenotype or genotype is recommended. The March 2026 update cites alloimmunization rates of 0.4–4.1% in treated myeloma cohorts as support for a more targeted approach; some institutions match only ABO/RhD and K (AABB Association Bulletin #16-02, 2023 and 2026 versions).
  • Crossmatch. With a negative screen against DTT-treated cells, an electronic or immediate-spin crossmatch with ABO/RhD-compatible, K-matched units is acceptable (AABB Association Bulletin #16-02).

Crossmatch methods

Crossmatch Procedure What it detects Use Source
Immediate spin Recipient plasma and donor red cells centrifuged and read at once; no incubation or antiglobulin phase Mainly ABO incompatibility Negative antibody screen and no history of clinically significant antibodies FDA 2011
Antiglobulin (major) Recipient plasma and donor red cells incubated and tested with antihuman globulin (AHG) Incompatibility from unexpected antibodies Current or historical clinically significant red cell antibodies FDA 2011
Minor Donor plasma tested with recipient red cells with incubation and AHG Donor antibodies to recipient antigens Only when the donor unit was not screened for unexpected antibodies FDA 2011; 21 CFR 606.151(d)
Computer (electronic) Software compares validated donor and recipient ABO/RhD records ABO incompatibility of the selected unit Two concordant recipient ABO/RhD determinations, no ABO discrepancy and no clinically significant antibodies FDA 2011; Butch 1994
  • Exclusions from computer crossmatch. A serologic crossmatch is used when the recipient has, or has had, clinically significant red cell antibodies, when an ABO typing discrepancy exists and when a donor unit carries clinically significant antibodies (FDA 2011).
  • ABO discrepancies that exclude computer crossmatch. Mixed-field reactivity, missing serum reactivity and an apparent change in blood type after hematopoietic stem cell transplantation are named examples (FDA 2011).
  • Benefits. At one institution, the computer crossmatch reduced sample volume, handling of biohazardous material and false reactions from the immediate-spin crossmatch. Tables built into the software blocked release of ABO-incompatible units (Butch 1994).

American Rare Donor Program

  • American Rare Donor Program (ARDP). The AABB and the American Red Cross formed the ARDP in 1998. Its database merged two rare donor files that began in the 1960s (Flickinger 2014).
ARDP category Definition Source
High-prevalence antigen negative Any ABO group; lacks an antigen of prevalence below 1 in 1,000 (U, Jsb, Kpb, Yta) Flickinger 2014
Multiple common antigen negative Group O or A; R1R1, R2R2, R0R0 or rr, and K−, and Fy(a−) or Fy(b−), and Jk(a−) or Jk(b−); or R1R1, R2R2 or rr, and K−, and Fy(a−b−) Flickinger 2014
IgA deficient Any ABO group; IgA below 0.05 mg/dL confirmed on two donations Flickinger 2014
  • Confirmation. Rare antigen-negative types are confirmed by two testing sources (Flickinger 2014).
  • Requests. A request requires that the patient has the corresponding antibody. ARDP staff search the database for member facilities with matching donors and coordinate shipment. When no units are found, members recruit donors, and an international search follows under FDA guidelines (Flickinger 2014).

red cell antibody specificity lookup

Blood Component Selection and Serologic Workup of Autoantibodies

Definition. Component selection is the choice of the ABO group, RhD type and modification of each blood component so that donor antigens and antibodies are compatible with the recipient. Emergency release is issue of blood before pretransfusion testing is complete. Issue and bedside verification are the final checks that the right component reaches the right patient. Autoantibodies and a positive direct antiglobulin test (DAT) complicate each of these steps. The rules for component selection in the United States are stated in the Circular of Information for the Use of Human Blood and Blood Components, which FDA recognizes as an extension of container labels (Circular of Information 2024).

Related page: Pretransfusion Testing, Antibody Identification, Crossmatch and Drug Interference (sample requirements, antibody identification and crossmatch) Related page: Immunohematology Methods in Red Cell Serology (antiglobulin test, adsorption and elution techniques) Related page: ABO and H Blood Group Systems and ABO Discrepancies (ABO antibodies and ABO discrepancies) Related page: The Rh Blood Group System: D, Weak and Partial D, RhCE Variants and Rh Typing Problems (RhD typing and weak and partial D) Related page: Transfusion Reactions (acute and delayed hemolytic transfusion reactions)

ABO and RhD rules for each blood component

The current Circular of Information is dated June 2024. FDA recognized it as acceptable in guidance issued in September 2024, which superseded the guidance of March 2022 that recognized the previous version (FDA 2024).

Component ABO rule Compatibility testing Source
Whole Blood ABO group-specific; group O whole blood may be given to non-group-O patients in life-threatening situations when the facility defines anti-A and anti-B titer cutoffs ABO/RhD typing, antibody screen and serologic or computer crossmatch Circular of Information 2024
Red Blood Cells ABO group compatible with the ABO antibodies in the recipient's plasma Serologic compatibility established before transfusion Circular of Information 2024
Plasma ABO compatible with the recipient's red cells Not necessary Circular of Information 2024
Platelets Donor plasma ABO compatible with the recipient's red cells for pediatric patients with small blood volumes Not necessary unless the unit contains 2 mL or more of red cells Circular of Information 2024
Cryoprecipitated AHF ABO-compatible product may be preferred in neonates Not necessary Circular of Information 2024
Apheresis Granulocytes Red cells must be ABO compatible Serologic compatibility established before transfusion Circular of Information 2024
Recipient ABO group Red cells compatible with recipient plasma Plasma compatible with recipient red cells
O O O, A, B, AB
A A, O A, AB
B B, O B, AB
AB AB, A, B, O AB

Compatibility by recipient ABO group follows from these two rules and the ABO antibodies of each group (ABO and H Blood Group Systems and ABO Discrepancies).

  • RhD selection of red cells. The D antigen is routinely matched, RhD-negative units to RhD-negative recipients, to prevent sensitization (Lange 2026). RhD-positive red cells or low-titer group O whole blood are given to RhD-negative patients in massive hemorrhage, as described below (Yazer 2021; Lange 2026).

  • RhD in plasma and cryoprecipitate. Compatibility with RhD is not necessary for plasma, and RhD need not be considered for cryoprecipitated AHF (Circular of Information 2024).

  • RhD exposure from platelets. RhD-positive platelets are often given to RhD-negative recipients. The risk of RhD alloimmunization is higher with whole-blood-derived platelets and very low with apheresis platelets, and Rh immune globulin may be considered in selected patients (Circular of Information 2024).

  • Incompatible plasma in platelets. Platelets that are not ABO identical can contain incompatible plasma and can cause a positive DAT (Circular of Information 2024). Hemolysis from such units is described in Transfusion Reactions.

  • Incompatible cryoprecipitated AHF. A large volume of ABO-incompatible cryoprecipitated AHF can cause a positive DAT (Circular of Information 2024).

  • Low-titer products. "Low" anti-A and anti-B titers are not standardized. Hemolysis has occurred at low titers, and each facility defines cutoffs for ABO-incompatible components (Circular of Information 2024).

  • Volume reduction. Removal of plasma by centrifugation reduces antibodies in the unit. It mitigates ABO incompatibility, transfusion-associated circulatory overload and severe allergic reactions and is used mainly in pediatric and intrauterine transfusion. Volume reduction does not replace washing or dosing with small aliquots (Circular of Information 2024).

  • Washing. Washing removes plasma proteins, including antibodies. It is indicated, for example, for maternal platelets given for neonatal alloimmune thrombocytopenia and for IgA-deficient recipients with anaphylactic reactions (Circular of Information 2024).

Emergency release of uncrossmatched blood

  • Federal requirement. Procedures expedite transfusion in life-threatening emergencies. Each case is recorded, with a justification signed by a physician (21 CFR 606.151(e)).
  • Red cells. When delay would be life-threatening, uncrossmatched group O red cells or ABO group-specific red cells may be transfused before compatibility testing is complete (Circular of Information 2024).
  • Group O whole blood and group A plasma. Group O whole blood and group A plasma tested for anti-A and anti-B may be used as initial resuscitation fluids before the recipient's blood group is known (Circular of Information 2024).
  • Facility policy. The transfusing facility defines indications, product specifications, administration instructions and a maximum number of units per patient (Circular of Information 2024).
  • Anti-CD38 therapy. Uncrossmatched ABO/RhD-compatible red cells may be given in an emergency according to local practice (AABB Association Bulletin #16-02).
  • Contraindication. ABO-incompatible products are not transfused when a compatible product is readily available or when risk outweighs benefit (Circular of Information 2024).

RhD-positive blood for RhD-negative recipients in massive hemorrhage

Finding Value Source
Anti-D after RhD-positive red cells or whole blood in injured RhD-negative patients aged 13–50 years 41 of 96 (42.7%; 95% CI 32.7–53.2%), after a median of 3 units Yazer 2021
Effect of leukoreduction or low-titer group O whole blood on that rate No association Yazer 2021
Pregnancies with immune anti-D that reached the critical titer of ≥16 60 of 97 (62%) Yazer 2024
Calculated perinatal mortality after RhD-positive transfusion in trauma 0.04% Yazer 2024
Calculated perinatal death or serious adverse event from hemolytic disease of the fetus and newborn 0.24% Yazer 2024
  • Institutional restrictions. One regional whole blood program first limited RhD-positive low-titer group O whole blood to males older than 10 years and females older than 50 years. Its later review judged RhD-positive whole blood justified in the resuscitation of females, including female children, in the acute trauma setting regardless of age or blood type (Lange 2026).
  • Rh immune globulin after RhD-mismatched transfusion. Each 20 µg (100 IU) of Rh immune globulin is given per 1 mL of RhD-positive red cells transfused, and therapy is given within 72 h of the mismatched transfusion. Pediatric females are eligible when the RhD-positive red cell volume transfused is below 20% of total blood volume. All are screened for anti-D 6–12 months after transfusion (Lange 2026).

Issue of components and bedside verification

The Circular of Information gives these general instructions for whole blood and all components.

Step Requirement Source
Identification The intended recipient and the container are identified before transfusion starts Circular of Information 2024
Inspection A unit with a broken container, excess hemolysis, a color change compared with the segments, floccular material or a cloudy appearance is not transfused, and the transfusion service is informed Circular of Information 2024
Filtration A sterile, pyrogen-free filter of generally 150–260 µm Circular of Information 2024
Solutions Only 0.9% Sodium Chloride Injection USP, unless FDA approval or documentation shows another addition is safe; calcium-containing solutions such as Lactated Ringer's are never given through the same line as citrated components Circular of Information 2024
Warming Used when indicated, for example in exchange or massive transfusion and in patients with cold-reactive antibodies; only FDA-cleared warmers Circular of Information 2024
Rate and monitoring Slow initial rate; vital signs before, during and after; transfusion stopped if a reaction occurs Circular of Information 2024
Opened system A unit entered in a way that breaks the closed system expires 4 h after entry at 20–24 °C or 24 h at 1–6 °C Circular of Information 2024

Cold autoantibodies in pretransfusion testing

Cold autoantibodies bind best at low temperature. Most are clinically insignificant, and some cause cold agglutinin disease (CAD).

Feature Finding Source
DAT in CAD Strongly positive for C3d; negative or weakly positive for IgG Berentsen 2019
Cold agglutinin titer in CAD Diagnostic criterion ≥64; some typical cases have lower titers Berentsen 2019
Thermal amplitude Highest temperature at which the antibody binds. Low-amplitude polyclonal cold agglutinins (below about 25–28 °C) occur in healthy persons Berentsen 2019
Antibody Usually monoclonal IgM κ with anti-I specificity (I system serology: Kell, Duffy, Kidd, MNS, Lewis, I, P1PK and Other Blood Group Systems, Nomenclature and Genotyping) Berentsen 2019
Specimen Kept at 37–38 °C from collection until serum or plasma is separated; cooling causes falsely low or negative results Berentsen 2019
Mixed autoimmune hemolytic anemia (AIHA) Warm autoantibody with a cold agglutinin titer of ≥64 Datta 2024
  • Prewarm method. It detects antibodies that bind at 37 °C and avoids antibodies that bind below 37 °C. It is used when cold autoantibodies of wide thermal range react at 37 °C and in the antiglobulin phase (Dupuis 2018).
  • Related laboratory techniques. The hazard of prewarming (a fatal anti-Vel case), rabbit red cell adsorption and dispersal of autoagglutination with DTT are described in Immunohematology Methods in Red Cell Serology.
  • Transfusion in CAD. Transfusion can be given safely when the patient and the infusion limb are kept warm and an in-line warmer is used. Screening and crossmatching may need to be performed at 37 °C (Berentsen 2019).
  • Paroxysmal cold hemoglobinuria (PCH). The Donath-Landsteiner antibody is a biphasic IgG hemolysin that binds red cells only in the cold and is not detected by the DAT. The DAT is positive for complement during and shortly after an attack and negative between attacks. In the Donath-Landsteiner test, fresh serum is incubated with red cells at 4 °C and then warmed to 37 °C, and hemolysis indicates a positive result. Titers rarely exceed 16. PCH accounts for about 2–5% of AIHA overall and almost one-third of AIHA in children, mostly after viral or upper respiratory infections (Packman 2015; Kilty 2019). The target antigen, formerly called P, is the antigen of the GLOB blood group system (Loriamini 2024). Its serology is covered in Kell, Duffy, Kidd, MNS, Lewis, I, P1PK and Other Blood Group Systems, Nomenclature and Genotyping.

Warm autoantibody workup before transfusion

  • Frequency and DAT pattern. Warm AIHA (wAIHA) accounts for 65–75% of AIHA. The DAT is positive for IgG or for IgG and complement. Complement is activated in about half of wAIHA (Datta 2024), and the DAT is positive for IgG and C3d in 50–60% (Salama 2015).
  • Monospecific DAT. The First International Consensus Meeting considers a monospecific DAT mandatory in the diagnostic workup of AIHA (Jäger 2020).
  • Alloantibodies underlying warm autoantibody. Panreactive warm autoantibody in plasma can prevent detection of clinically significant alloantibodies. Adsorption is usually required to confirm or exclude them (Heuft 2015; Barron 2014). Their frequency and the adsorption methods, with their limitations, are given in Immunohematology Methods in Red Cell Serology.
  • Antigen-matched units. Pretransfusion testing in AIHA includes ABO, CcDEe and K typing with alloantibody assessment, and an extended phenotype when time allows (Datta 2024).
  • "Least incompatible" units. The term was challenged as meaningless in 2003 (Petz 2003). Experts consider it obsolete, and the practice exposes patients to delayed hemolytic transfusion reactions (Datta 2024). Issuing "least incompatible" or Rh- and K-matched blood without adsorption studies is not appropriate (Maley 2005).
  • Indications for transfusion. Many patients with AIHA need transfusion, at least temporarily, because no drug stops severe hemolysis immediately (Heuft 2015).

Workup of a positive direct antiglobulin test

The DAT detects immunoglobulin, complement or both on red cells. Its role is to separate immune from nonimmune hemolysis (Zantek 2012).

Clinical setting Typical serologic finding Source
Warm AIHA IgG, or IgG and complement Datta 2024
CAD C3d strongly positive; IgG negative or weak Berentsen 2019
Paroxysmal cold hemoglobinuria Complement only during and shortly after an attack; IgG not detected; positive Donath-Landsteiner test Packman 2015; Kilty 2019
Transfusion-related hemolysis, hemolytic disease of the fetus and newborn, passenger lymphocyte syndrome Positive DAT Zantek 2012
Drug-induced immune hemolytic anemia Drug-dependent or drug-independent antibody Leger 2014
Anti-CD38 therapy IgG DAT and autocontrol may be positive (Pretransfusion Testing, Antibody Identification, Crossmatch and Drug Interference) AABB Association Bulletin #16-02
ABO-nonidentical platelets or large volumes of incompatible cryoprecipitated AHF Positive DAT from passively transfused anti-A or anti-B Circular of Information 2024
  • False results. Improper washing, centrifugation and agitation during reading cause false results. Spontaneous agglutination of the patient's red cells also interferes (Zantek 2012).
  • Eluate when only C3 is detected. The yield of elution from red cells coated with complement alone is given in Immunohematology Methods in Red Cell Serology.

Drug-induced immune hemolytic anemia

  • Indications for drug antibody testing. Testing is warranted with definite immune hemolysis, exclusion of common causes and a close temporal link to a drug (Leger 2014).
  • Drug-dependent antibodies. They require the drug in the test. They are detected with drug-treated red cells or with untreated red cells in the presence of a drug solution (Arndt 2014; Leger 2014).
  • Drug-independent antibodies. They react without drug and cannot be distinguished serologically from warm autoantibodies (Leger 2014).
  • Nonimmunologic protein adsorption. Some drugs cause adsorption of proteins, including immunoglobulins, onto red cells without antibody formation. Nonimmunologic protein adsorption can also cause immune hemolytic anemia (Leger 2014; Loriamini 2024).
  • Drugs implicated. More than 130 drugs have been suspected. A French nationwide study associated immune hemolytic anemia with some antibiotics, antifungal drugs, ibuprofen, acetaminophen, furosemide, azathioprine and iomeprol (Maquet 2024).
Mechanism Test that shows the antibody Examples Source
Drug binding to the red cell membrane (hapten) Drug-treated red cells Penicillin and cephalosporins Loriamini 2024
Neoantigen Untreated red cells with drug in solution Second- and third-generation cephalosporins such as cefotetan and ceftriaxone Loriamini 2024
Cross-reactive (drug-induced) autoantibody Reacts without drug; DAT positive for IgG; indistinguishable from warm autoantibody Methyldopa, with hemolysis that can appear months after the drug is started Loriamini 2024; Leger 2014
Nonimmunologic protein adsorption No antibody; proteins taken up by the red cells Drugs that coat red cells Leger 2014; Loriamini 2024
  • Common drugs. Most cases are caused by second- and third-generation cephalosporins, cefotetan and ceftriaxone (Packman 2015). In a 20-year single-center series of 73 patients, the most frequent drugs were diclofenac, piperacillin, ceftriaxone and oxaliplatin. The DAT was positive at least for C3d in 65 (89%), and 17 (23%) died (Mayer 2015).
  • Ceftriaxone. Ceftriaxone antibodies are mainly IgM, and the red cells are almost always coated with C3d. In the cases reported by Garratty, hemolysis was fatal in 36% of ceftriaxone cases and 19% of cefotetan cases (Mayer 2015).

References

  1. AABB, American Red Cross, America's Blood Centers, Armed Services Blood Program. Circular of Information for the Use of Human Blood and Blood Components. June 2024. https://www.aabb.org/news-resources/resources/circular-of-information
  2. AABB. Standards for Immunohematology Reference Laboratories, 13th edition (effective April 1, 2024), AABB Store listing. https://www.aabb.org/aabb-store/product/standards-for-immunohematology-reference-laboratories-13th-edition-print-and-portal-17356819
  3. AABB. AABB outlines notable changes to upcoming BB/TS Standards, IRL Standards. AABB News, 11 February 2026. https://www.aabb.org/news-resources/news/article/2026/02/11/aabb-outlines-notable-changes-to-upcoming-bb-ts-standards--irl-standards
  4. AABB. AABB outlines notable changes to upcoming BB/TS Standards, IRL Standards. February 11, 2026. https://www.aabb.org/news-resources/news/article/2026/02/11/aabb-outlines-notable-changes-to-upcoming-bb-ts-standards--irl-standards
  5. AABB. AABB releases 35th edition of BB/TS Standards. March 2, 2026. https://www.aabb.org/news-resources/news/article/2026/03/02/aabb-releases-35th-edition-of-bb-ts-standards
  6. AABB. Association Bulletin #16-02: Mitigating the anti-CD38 interference with serologic testing. January 15, 2016; updated April 2023 and March 2026. https://www.aabb.org/docs/default-source/default-document-library/resources/association-bulletins/ab16-02.pdf
  7. Alba Bioscience. Anti-Human Globulin Anti-IgG (Rabbit) for tube technique, package insert (STN BL 125464). https://www.fda.gov/media/107535/download
  8. Aldarweesh FA, Abdallah R, Alvarez IP, et al. D-alloantibody titration assessment study: in search of a common antibody titration platform—a BEST Collaborative study. Transfusion. 2026;66(1):94–101. doi:10.1111/trf.70022. PMID 41386683
  9. American College of Obstetricians and Gynecologists. ACOG Clinical Practice Update: Rh D immune globulin administration after abortion or pregnancy loss at less than 12 weeks of gestation. Obstet Gynecol. 2024;144(6):e140–e143. doi:10.1097/AOG.0000000000005733. PMID 39255498
  10. American College of Obstetricians and Gynecologists. Practice Bulletin No. 181: prevention of Rh D alloimmunization. Obstet Gynecol. 2017;130(2):e57–e70. doi:10.1097/AOG.0000000000002232. PMID 28742673
  11. American Red Cross. Blood Grouping Reagent Anti-k (Monoclonal) (IgG), package insert. https://www.fda.gov/media/189767/download
  12. Arndt PA. Drug-induced immune hemolytic anemia: the last 30 years of changes. Immunohematology. 2014;30(2):44–54. PMID 25247622
  13. Asiimwe E, Ngo TP, Ziv E, Leavitt AD. Duffy-null variant and practical implications for patient care: a scoping review. BMJ Open. 2025;15(11):e099049. doi:10.1136/bmjopen-2025-099049. PMID 41263834
  14. Bajpai M, Kaur R, Gupta E. Automation in immunohematology. Asian J Transfus Sci. 2012;6(2):140–144. doi:10.4103/0973-6247.98914. PMID 22988378
  15. Barriteau CM, Lindholm PF, Hartman K, et al. RHD genotyping to resolve weak and discrepant RhD patient phenotypes. Transfusion. 2022;62(11):2194–2199. doi:10.1111/trf.17145. PMID 36218305
  16. Barron C. Allogeneic red blood cell adsorption for removal of warm autoantibody. Immunohematology. 2014;30(4):153–155. PMID 25831261
  17. Berentsen S, Röth A, Randen U, Jilma B, Tjønnfjord GE. Cold agglutinin disease: current challenges and future prospects. J Blood Med. 2019;10:93–103. doi:10.2147/JBM.S177621. PMID 31114413
  18. Berentsen S. Cold agglutinin disease. Hematology Am Soc Hematol Educ Program. 2016;2016(1):226–231. doi:10.1182/asheducation-2016.1.226. PMID 27913484
  19. Biotest AG for Olympus America. Anti-IgG Solidscreen II, package insert. https://www.fda.gov/media/75557/download
  20. Branch DR, Petz LD. A new reagent (ZZAP) having multiple applications in immunohematology. Am J Clin Pathol. 1982;78(2):161–167. doi:10.1093/ajcp/78.2.161. PMID 6808844
  21. Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science. 1993;262(5130):114–117. doi:10.1126/science.8211117. PMID 8211117
  22. Bruce B. Enzyme treatment of red blood cells: use of ficin and papain. Immunohematology. 2022;38(3):90–95. doi:10.21307/immunohematology-2022-048. PMID 36190201
  23. Bub CB. Dithiothreitol treatment of red blood cells. Immunohematology. 2017;33(4):170–172. doi:10.21307/immunohematology-2019-025. PMID 29378150
  24. Butch SH, Judd WJ, Steiner EA, Stoe M, Oberman HA. Electronic verification of donor-recipient compatibility: the computer crossmatch. Transfusion. 1994;34(2):105–109. doi:10.1046/j.1537-2995.1994.34294143935.x. PMID 8310478
  25. Byrne KM, Mercado CMC, Nnabue TN, et al. Inhibition of blood group antibodies by soluble substances. Immunohematology. 2019;35(1):19–22. PMID 30908075
  26. Cartron JP. RH blood group system and molecular basis of Rh-deficiency. Baillieres Best Pract Res Clin Haematol. 1999;12(4):655–689. doi:10.1053/beha.1999.0047. PMID 10895258
  27. Centers for Medicare & Medicaid Services. 42 CFR 493.1256 (Standard: control procedures) and 493.1271 (Standard: immunohematology). Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-G/part-493
  28. Centers for Medicare & Medicaid Services. 42 CFR 493.1271, Standard: immunohematology. Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-G/part-493/subpart-K/section-493.1271
  29. Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015;55(6 Pt 2):1545–1554. doi:10.1111/trf.13069. PMID 25764134
  30. Chou ST, Jackson T, Vege S, et al. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood. 2013;122(6):1062–1071. doi:10.1182/blood-2013-03-490623. PMID 23723452
  31. Chun S, Choi S, Yu H, et al. Cis-AB, the blood group of many faces, is a conundrum to the novice eye. Ann Lab Med. 2019;39(2):115–120. doi:10.3343/alm.2019.39.2.115. PMID 30430772
  32. Ciobanu AM, Dumitru AE, Gica N, et al. Benefits and risks of IgG transplacental transfer. Diagnostics (Basel). 2020;10(8):583. doi:10.3390/diagnostics10080583. PMID 32806663
  33. Clausen FB, van der Schoot CE. Noninvasive fetal blood group antigen genotyping. Blood Transfus. 2025;23(2):101–108. doi:10.2450/BloodTransfus.712. PMID 38315532
  34. Cobaugh A. Adsorption of cold agglutinins with rabbit red blood cells. Immunohematology. 2018;34(2):46–48. PMID 29989418
  35. Coombs RRA, Mourant AE, Race RR. A new test for the detection of weak and "incomplete" Rh agglutinins. Br J Exp Pathol. 1945;26(4):255–266. PMID 21006651
  36. Crottet SL. Clinical significance of antibodies to antigens in the Scianna, Dombrock, Colton, Landsteiner-Wiener, Chido/Rodgers, H, Kx, Cromer, Gerbich, Knops, Indian, and Ok blood group systems. Immunohematology. 2018;34(3):103–108. PMID 30295505
  37. Dara RC, Tiwari AK, Mitra S, et al. Comparison of a column agglutination technology-based automated immunohematology analyzer and a semiautomated system in pretransfusion testing. Asian J Transfus Sci. 2019;13(2):115–119. doi:10.4103/ajts.ajts_116_17. PMID 31896918
  38. Das SS, Biswas RN, Safi M. "Auto-anti-A1" in a healthy young blood donor: a rare cause of ABO discrepancy. Asian J Transfus Sci. 2021;15(1):87–89. doi:10.4103/ajts.AJTS_42_20. PMID 34349463
  39. Datta SS, Basu S, Reddy M, Gupta K, Sinha S. Comparative evaluation of the conventional tube test and column agglutination technology for ABO antibody titration in healthy individuals: a report from India. Immunohematology. 2021;37(1):25–32. doi:10.21307/immunohematology-2021-006. PMID 33962486
  40. Datta SS, Berentsen S. Management of autoimmune haemolytic anaemia in low-to-middle income countries: current challenges and the way forward. Lancet Reg Health Southeast Asia. 2024;23:100343. doi:10.1016/j.lansea.2023.100343. PMID 38601175
  41. Davison CL, Denomme GA. Kell and Kx blood group systems: an update. Immunohematology. 2025;41(3):90–99. doi:10.2478/immunohematology-2025-014. PMID 41168991
  42. Dean-El C, Quraishy N. Heat elution: a modification of the Landsteiner-Miller method. Immunohematology. 2019;35(2):45–47. PMID 31246486
  43. Deelert S, Thippayaboon P, Sriwai W, et al. Jk(a-b-) phenotype screening by the urea lysis test in Thai blood donors. Blood Transfus. 2010;8(1):17–20. doi:10.2450/2009.0104-09. PMID 20104274
  44. Deerej P, Prakash S, Nagrath P, et al. A case report of a delayed hemolytic transfusion reaction due to anamnestic response by anti-Kidd "b" in an orthopedic patient. Asian J Transfus Sci. 2026;20(2):485–489. doi:10.4103/ajts.ajts_203_24. PMID 42953507
  45. Denomme GA. Kell and Kx blood group systems. Immunohematology. 2015;31(1):14–19. PMID 26308465
  46. Desai P, Navkudkar A, Rajadhyaksha S. ABO blood group discrepancies in blood donor and patient samples at a tertiary care oncology centre: analysis and serological resolution. Hematol Transfus Cell Ther. 2024;46(4):402–407. doi:10.1016/j.htct.2023.07.011. PMID 37690977
  47. Di Ciaccio P, Cutts B, Alahakoon TI, et al. Clinical consequences of the extremely rare anti-PP1Pk isoantibodies in pregnancy: a case series and review of the literature. Vox Sang. 2021;116(5):591–600. doi:10.1111/vox.13042. PMID 33326620
  48. Dupuis S. Use of the prewarm method for detecting clinically significant alloantibodies in the presence of cold autoantibodies. Immunohematology. 2018;34(4):148–150. PMID 30624948
  49. Ekema EM. Separation of multiple antibodies by adsorption with allogeneic red blood cells. Immunohematology. 2017;33(4):155–158. doi:10.21307/immunohematology-2019-022. PMID 29378147
  50. Fernandes HP, Cesar CL, Barjas-Castro ML. Electrical properties of the red blood cell membrane and immunohematological investigation. Rev Bras Hematol Hemoter. 2011;33(4):297–301. doi:10.5581/1516-8484.20110080. PMID 23049321
  51. Figueroa D. The Diego blood group system: a review. Immunohematology. 2013;29(2):73–81. PMID 24094240
  52. Flickinger C. REGGI and the American Rare Donor Program. Transfus Med Hemother. 2014;41(5):342–345. doi:10.1159/000366149. PMID 25538535
  53. Fraser NS, Knauth CM, Moussa A, et al. Genetic variants within the erythroid transcription factor, KLF1, and reduction of the expression of Lutheran and other blood group antigens: review of the In(Lu) phenotype. Transfus Med Rev. 2019;33(2):111–117. doi:10.1016/j.tmrv.2019.01.004. PMID 31023581
  54. Furqan M, Rana MA, Iloke CV, et al. Anti-Jka-mediated delayed hemolytic transfusion reaction mimicking warm autoimmune hemolytic anemia in a multiparous woman: a case report. Ann Med Surg (Lond). 2026;88(6):3729–3733. doi:10.1097/MS9.0000000000005060. PMID 42254262
  55. Gassner C, Denomme GA, Portmann C, et al. Two prevalent ∼100-kb GYPB deletions causative of the GPB-deficient blood group MNS phenotype S-s-U- in Black Africans. Transfus Med Hemother. 2020;47(4):326–336. doi:10.1159/000504946. PMID 32884505
  56. Guo ZH, Xiang D, Zhu ZY, et al. Serologic and molecular characterization of the B(A) blood group in the Chinese population. Immunohematology. 2007;23(2):69–74. PMID 18004937
  57. Hagman JR, Rahfeld P, Withers SG, et al. Use of a recombinant deacetylase to convert A1 red blood cells to the acquired B phenotype for quality control purposes. Blood Transfus. 2024;22(2):106–110. doi:10.2450/BloodTransfus.584. PMID 37847210
  58. Hamilton JR. Kidd blood group system: a review. Immunohematology. 2015;31(1):29–35. PMID 26308468
  59. Harach ME, Gould JM, Brown RP, et al. Method-specific and unexplained reactivity in automated solid-phase testing and their association with specific antibodies. Immunohematology. 2018;34(3):93–97. PMID 30295503
  60. Harris RE, Hochman HG. Revised P values in testing blood group antibodies: Fisher's exact test revisited. Transfusion. 1986;26(6):494–499. doi:10.1046/j.1537-2995.1986.26687043612.x. PMID 3775831
  61. Hellberg Å, Westman JS, Thuresson B, Olsson ML. P1PK: the blood group system that changed its name and expanded. Immunohematology. 2013;29(1):25–33. PMID 24046920
  62. Heuft HG, Pruß A. Autoimmune hemolytic anemia—fascinating from a laboratory as well as from a clinical point of view. Transfus Med Hemother. 2015;42(5):276–277. doi:10.1159/000441157. PMID 26696794
  63. Hinrichs M, Keith MA. Cold acid elution (ELU Kit II). Immunohematology. 2014;30(3):113–116. PMID 25695435
  64. Ho M, Chelly J, Carter N, et al. Isolation of the gene for McLeod syndrome that encodes a novel membrane transport protein. Cell. 1994;77(6):869–880. doi:10.1016/0092-8674(94)90136-8. PMID 8004674
  65. Hyland CA, Castilho L, Chen Q, et al. International Society of Blood Transfusion Working Party on Red Cell Immunogenetics and Blood Group Terminology report of Gothenburg, Barcelona and four virtual business meetings: update on blood group systems. Vox Sang. 2026;121(2):202–212. doi:10.1111/vox.70148. PMID 41326325
  66. International Society of Blood Transfusion. Table of blood group systems, v12.0, 31 May 2025. https://www.isbtweb.org/resource/tableofbloodgroupsystems.html
  67. International Society of Blood Transfusion. Blood group terminology; Red Cell Immunogenetics and Blood Group Terminology Working Party registry page (updated 24 September 2026). https://www.isbtweb.org/isbt-working-parties/rcibgt.html
  68. International Society of Blood Transfusion. ISBT announcement about the new PIGZ blood group system. 22 August 2025. https://www.isbtweb.org/resource/isbt-announcement-about-the-new-pigz-blood-group-system.html
  69. International Society of Blood Transfusion. ISBT Blood Group Database. https://blooddatabase.isbtweb.org/database (accessed 10 November 2026)
  70. Jacobs JW, Figueroa Villalba CA, Booth GS, et al. Clinical and epidemiological features of paroxysmal cold hemoglobinuria: a systematic review. Blood Adv. 2023;7(11):2520–2527. doi:10.1182/bloodadvances.2022009516. PMID 36716137
  71. Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting. Blood Rev. 2020;41:100648. doi:10.1016/j.blre.2019.100648. PMID 31839434
  72. Jain A, Gupta A, Malhotra S, et al. An ABO blood grouping discrepancy: probable B(A) phenotype. Transfus Apher Sci. 2017;56(3):459–460. doi:10.1016/j.transci.2017.05.002. PMID 28571931
  73. Kanter MH, Poole G, Garratty G. Misinterpretation and misapplication of p values in antibody identification: the lack of value of a p value. Transfusion. 1997;37(8):816–822. doi:10.1046/j.1537-2995.1997.37897424404.x. PMID 9280326
  74. Kelly RJ, Ernst LK, Larsen RD, et al. Molecular basis for H blood group deficiency in Bombay (Oh) and para-Bombay individuals. Proc Natl Acad Sci U S A. 1994;91(13):5843–5847. doi:10.1073/pnas.91.13.5843. PMID 7912436
  75. Kilty M, Ipe TS. Donath-Landsteiner test. Immunohematology. 2019;35(1):3–6. PMID 30908069
  76. Kokoris SI, Kalantzis D, Moschandreou D, Papaioannou K, Grouzi E. Panagglutination on the indirect antiglobulin test... this is the challenge! Asian J Transfus Sci. 2022;16(2):257–262. doi:10.4103/ajts.ajts_133_20. PMID 36687552
  77. Kwon DH, Sandler SG, Flegel WA. DEL phenotype. Immunohematology. 2017;33(3):125–132. PMID 29043831
  78. Lahare S, Chandrakar R, Wasnik M. A case report on weak subgroup of A: A(end). Asian J Transfus Sci. 2024;18(2):330–332. doi:10.4103/ajts.AJTS_37_19. PMID 39822690
  79. Laine EP, Leger RM, Arndt PA, Calhoun L, Garratty G, Petz LD. In vitro studies of the impact of transfusion on the detection of alloantibodies after autoadsorption. Transfusion. 2000;40(11):1384–1387. doi:10.1046/j.1537-2995.2000.40111384.x. PMID 11099669
  80. Lange K, Bowers A, Raghavan N, et al. Early exposure, enduring consequences: how do I manage Rh immunoglobulin prophylaxis after Rh-mismatched transfusions in children? Transfusion. 2026;66(Suppl 1):S391–S401. doi:10.1111/trf.70094. PMID 41693223
  81. Lapierre Y, Rigal D, Adam J, et al. The gel test: a new way to detect red cell antigen-antibody reactions. Transfusion. 1990;30(2):109–113. doi:10.1046/j.1537-2995.1990.30290162894.x. PMID 2305438
  82. Lee S, Russo D, Redman CM. The Kell blood group system: Kell and XK membrane proteins. Semin Hematol. 2000;37(2):113–121. doi:10.1016/s0037-1963(00)90036-2. PMID 10791880
  83. Leger RM, Arndt PA, Garratty G. How we investigate drug-induced immune hemolytic anemia. Immunohematology. 2014;30(2):85–94. PMID 25247618
  84. Leger RM, Garratty G. Evaluation of methods for detecting alloantibodies underlying warm autoantibodies. Transfusion. 1999;39(1):11–16. doi:10.1046/j.1537-2995.1999.39199116889.x. PMID 9920161
  85. Lim YA, Park SJ, Cho HS. Investigation of discrepant ABO blood grouping results from an autoanalyzer. Ann Lab Med. 2022;42(6):650–658. doi:10.3343/alm.2022.42.6.650. PMID 35765873
  86. Loriamini M, Cserti-Gazdewich C, Branch DR. Autoimmune hemolytic anemias: classifications, pathophysiology, diagnoses and management. Int J Mol Sci. 2024;25(8):4296. doi:10.3390/ijms25084296. PMID 38673882
  87. Löw B, Messeter L. Antiglobulin test in low-ionic strength salt solution for rapid antibody screening and cross-matching. Vox Sang. 1974;26(1):53–61. doi:10.1111/j.1423-0410.1974.tb02666.x. PMID 4420622
  88. Ma X, Zhao Z, Zhang Y, Li L, Zhong J. A review of the Knops blood group system. Clin Appl Thromb Hemost. 2024;30:10760296241309638. doi:10.1177/10760296241309638. PMID 39706812
  89. Makroo RN, Bhatia A, Gupta R, et al. Prevalence of Rh, Duffy, Kell, Kidd & MNSs blood group antigens in the Indian blood donor population. Indian J Med Res. 2013;137(3):521–526. PMID 23640559
  90. Maley M, Bruce DG, Babb RG, Wells AW, Williams M. The incidence of red cell alloantibodies underlying panreactive warm autoantibodies. Immunohematology. 2005;21(3):122–125. PMID 16178670
  91. Manduzio P. Alloantibody identification: the importance of temperature, strength reaction and enzymes: a practical approach. Hematol Rep. 2024;16(4):815–824. doi:10.3390/hematolrep16040077. PMID 39728007
  92. Maquet J, Lafaurie M, Michel M, Lapeyre-Mestre M, Moulis G. Drug-induced immune hemolytic anemia: detection of new signals and risk assessment in a nationwide cohort study. Blood Adv. 2024;8(3):817–826. doi:10.1182/bloodadvances.2023009801. PMID 37782770
  93. Mattaloni SM, Arnoni C, Céspedes R, et al. Clinical significance of an alloantibody against the Kell blood group glycoprotein. Transfus Med Hemother. 2017;44(1):53–57. doi:10.1159/000448381. PMID 28275334
  94. Mayer B, Bartolmäs T, Yürek S, Salama A. Variability of findings in drug-induced immune haemolytic anaemia: experience over 20 years in a single centre. Transfus Med Hemother. 2015;42(5):333–339. doi:10.1159/000440673. PMID 26696803
  95. Mayr G, Bublitz M, Steiert TA, et al. A structure-based in silico analysis of the Kell blood group system. Front Immunol. 2024;15:1452637. doi:10.3389/fimmu.2024.1452637. PMID 39726599
  96. Meny GM. The Duffy blood group system: a review. Immunohematology. 2010;26(2):51–56. PMID 20932074
  97. Merz LE, Story CM, Osei MA, et al. Absolute neutrophil count by Duffy status among healthy Black and African American adults. Blood Adv. 2023;7(3):317–320. doi:10.1182/bloodadvances.2022007679. PMID 35994632
  98. Meyer BM. The utility of an acid elution when a direct antiglobulin test is positive due to complement alone. Immunohematology. 2025;41(2):54–60. doi:10.2478/immunohematology-2025-009. PMID 40629488
  99. Miller LH, Mason SJ, Clyde DF, McGinniss MH. The resistance factor to Plasmodium vivax in blacks: the Duffy-blood-group genotype, FyFy. N Engl J Med. 1976;295(6):302–304. doi:10.1056/NEJM197608052950602. PMID 778616
  100. Moiz B, Hasan M, Salman M, et al. Anti-LW masquerading as anti-D in a D+ patient. Immunohematology. 2025;41(1):11–16. doi:10.2478/immunohematology-2025-0004. PMID 40146180
  101. Mougey R. A review of the Chido/Rodgers blood group. Immunohematology. 2010;26(1):30–38. PMID 20795316
  102. Nance SJ, Garratty G. A new potentiator of red blood cell antigen-antibody reactions. Am J Clin Pathol. 1987;87(5):633–635. doi:10.1093/ajcp/87.5.633. PMID 3578138
  103. Ogasawara K, Sano R, Kominato Y. Review of ABO expression and variations based on transcriptional regulation of the ABO blood group gene. Transfus Med Hemother. 2024;51(4):210–224. doi:10.1159/000536556. PMID 39135854
  104. Olivès B, Mattei MG, Huet M, et al. Kidd blood group and urea transport function of human erythrocytes are carried by the same protein. J Biol Chem. 1995;270(26):15607–15610. doi:10.1074/jbc.270.26.15607. PMID 7797558
  105. Ortho Clinical Diagnostics. Blood Grouping Reagent Anti-K (Monoclonal) ORTHO Sera, instructions for use, version 5.0, Pub. No. J39988_US_EN, Reaction Grading Guide. https://www.fda.gov/media/147816/download
  106. Packman CH. The clinical pictures of autoimmune hemolytic anemia. Transfus Med Hemother. 2015;42(5):317–324. doi:10.1159/000440656. PMID 26696800
  107. Petz LD. "Least incompatible" units for transfusion in autoimmune hemolytic anemia: should we eliminate this meaningless term? A commentary for clinicians and transfusion medicine professionals. Transfusion. 2003;43(11):1503–1507. doi:10.1046/j.1537-2995.2003.00583.x. PMID 14617306
  108. Pourazar A. Red cell antigens: structure and function. Asian J Transfus Sci. 2007;1(1):24–32. doi:10.4103/0973-6247.28069. PMID 21938229
  109. Reid ME. MNS blood group system: a review. Immunohematology. 2009;25(3):95–101. PMID 20406014
  110. Rosenfield RE, Schmidt PJ, Calvo RC, McGinniss MH. Anti-i, a frequent cold agglutinin in infectious mononucleosis. Vox Sang. 1965;10(5):631–634. doi:10.1111/j.1423-0410.1965.tb01418.x. PMID 5864820
  111. Routray SS, Ray GK, Sahoo N, et al. Serological weak expression of D antigen: a retrospective study of blood donors and patients at a teaching hospital in eastern India. Cureus. 2024;16(12):e75125. doi:10.7759/cureus.75125. PMID 39759727
  112. Saidin NIS, Anuar NAC, Hassan MN, et al. Rare subgroup of A phenotype: a case series. Asian Biomed (Res Rev News). 2026;20(3):202–205. doi:10.2478/abm-2026-0023. PMID 42541217
  113. Salama A. Clinically and/or serologically misleading findings surrounding immune haemolytic anaemias. Transfus Med Hemother. 2015;42(5):311–315. doi:10.1159/000438960. PMID 26696799
  114. Salarvand S, Nozheh A, Abdollahi A, et al. Hemolytic transfusion reaction due to anti Jk antibody, a frequently transient and low-titer antibody probably not detected in pretransfusion testing; a case report. Clin Case Rep. 2025;13(8):e70696. doi:10.1002/ccr3.70696. PMID 40756090
  115. Sandler SG, Flegel WA, Westhoff CM, et al. It's time to phase in RHD genotyping for patients with a serologic weak D phenotype. College of American Pathologists Transfusion Medicine Resource Committee Work Group. Transfusion. 2015;55(3):680–689. doi:10.1111/trf.12941. PMID 25438646
  116. Soejima M, Koda Y. FUT1 variants responsible for Bombay or para-Bombay phenotypes in a database. Sci Rep. 2023;13(1):17447. doi:10.1038/s41598-023-44731-1. PMID 37838738
  117. Srivastava K, Almarry NS, Flegel WA. Genetic variation of the whole ICAM4 gene in Caucasians and African Americans. Transfusion. 2014;54(9):2315–2324. doi:10.1111/trf.12615. PMID 24673173
  118. Stenfelt L, Hellberg Å, Olsson ML. SID: a new carbohydrate blood group system based on a well-characterized but still mysterious antigen of great pathophysiologic interest. Immunohematology. 2023;39(1):1–10. doi:10.21307/immunohematology-2023-002. PMID 37017600
  119. Storry JR, Mallory D. Misidentification of anti-Vel due to inappropriate use of prewarming and adsorption techniques. Immunohematology. 1994;10(3):83–86. PMID 15945800
  120. Storry JR, Peyrard T. The Vel blood group system: a review. Immunohematology. 2017;33(2):56–59. doi:10.21307/immunohematology-2019-008. PMID 28657763
  121. Subramaniyan R. AB para-Bombay phenotype: a rare blood group variant and its clinical significance. Hematol Transfus Cell Ther. 2018;40(1):96–97. doi:10.1016/j.htct.2017.11.003. PMID 30057978
  122. Sulin K, Arvas M, Toivonen S, et al. Comparison of conventional tube technique with automated gel microcolumn assay for antenatal antibody monitoring. Vox Sang. 2025;120(7):708–713. doi:10.1111/vox.70042. PMID 40301701
  123. Tondon R, Kataria R, Chaudhry R. Anti-M: report of two cases and review of literature. Asian J Transfus Sci. 2008;2(2):81–83. doi:10.4103/0973-6247.42695. PMID 20041082
  124. Toshniwal PU, Krishnan L, Kingsley S, et al. Maternal serum and cord blood anti-A and anti-B antibody levels as a predictor of significant hyperbilirubinemia in newborns. Asian J Transfus Sci. 2025;19(1):73–78. doi:10.4103/ajts.ajts_182_21. PMID 40837975
  125. Tournamille C, Colin Y, Cartron JP, Le Van Kim C. Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. Nat Genet. 1995;10(2):224–228. doi:10.1038/ng0695-224. PMID 7663520
  126. University of Toronto. LearnSerology, module 4: Approach to the antibody panel. https://pie.med.utoronto.ca/learnserology/LearnSerology_content/LS4_Appraoch_to_the_Antibody_Panel.html
  127. US Food and Drug Administration. Acceptable Circular of Information for the Use of Human Blood and Blood Components; Guidance for Industry. September 2024. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acceptable-circular-information-use-human-blood-and-blood-components
  128. US Food and Drug Administration. Guidance for Industry: "Computer Crossmatch" (Computerized Analysis of the Compatibility between the Donor's Cell Type and the Recipient's Serum or Plasma Type). April 2011. https://www.fda.gov/media/80857/download
  129. US Food and Drug Administration. 21 CFR 606.151, Compatibility testing. Code of Federal Regulations, April 1, 1999 edition. https://www.govinfo.gov/content/pkg/CFR-1999-title21-vol7/xml/CFR-1999-title21-vol7-sec606-151.xml
  130. US Food and Drug Administration. 21 CFR 606.151, Compatibility testing. Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-606/subpart-G/section-606.151
  131. US Food and Drug Administration. 21 CFR 640.5, Testing the blood. Electronic Code of Federal Regulations, accessed November 2026. https://www.ecfr.gov/current/title-21
  132. US Food and Drug Administration. 21 CFR 640.5(c), Determination of the Rh factors. Electronic Code of Federal Regulations, accessed November 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-640/subpart-A/section-640.5
  133. US Food and Drug Administration. 21 CFR Part 660, Subpart D (Reagent Red Blood Cells). Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-660/subpart-D
  134. US Food and Drug Administration. 21 CFR Part 660, Subparts D and F (Reagent Red Blood Cells; Anti-Human Globulin). Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-660
  135. US Food and Drug Administration. Immucor PreciseType Human Erythrocyte Antigen (HEA) Molecular BeadChip Test (BP130026). Approved Blood Products. https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/immucor-precisetype-human-erythrocyte-antigen-hea-molecular-beadchip-test
  136. Valentini B, Ramirez Zegarra R, Ghi T, et al. Red blood cell alloimmunization and pregnancy: diagnosis and management. Pregnancy (Hoboken). 2025;1(5):e70085. doi:10.1002/pmf2.70085. PMID 42597218
  137. Vaughan JI, Manning M, Warwick RM, et al. Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. N Engl J Med. 1998;338(12):798–803. doi:10.1056/NEJM199803193381204. PMID 9504940
  138. Wagner FF, Flegel WA. Review: the molecular basis of the Rh blood group phenotypes. Immunohematology. 2004;20(1):23–36. doi:10.21307/immunohematology-2019-419. PMID 15373666
  139. Walker L. Low-ionic-strength saline solution-antiglobulin test (LISS-AGT). Immunohematology. 2018;34(2):57–60. PMID 29989420
  140. Watkins CE, Litchfield J, Song E, et al. Chronic granulomatous disease, the McLeod phenotype and the contiguous gene deletion syndrome: a review. Clin Mol Allergy. 2011;9:13. doi:10.1186/1476-7961-9-13. PMID 22111908
  141. Westhoff CM, Reid ME. Review: the Kell, Duffy, and Kidd blood group systems. Immunohematology. 2004;20(1):37–49. PMID 15373667
  142. Wilson EM, Branch DR. Human red blood cell stroma: an alternative to traditional allogeneic adsorption methods. Transfusion. 2019;59(12):3736–3745. doi:10.1111/trf.15585. PMID 31710381
  143. Wipplinger M, Mink S, Bublitz M, Gassner C. Regulation of the Lewis blood group antigen expression: a literature review supplemented with computational analysis. Transfus Med Hemother. 2024;51(4):225–236. doi:10.1159/000538863. PMID 39135855
  144. Wongba K, Nuchnoi P, Plabplueng C, et al. Anti-IH in myelodysplastic syndrome. Pract Lab Med. 2025;45:e00468. doi:10.1016/j.plabm.2025.e00468. PMID 40242488
  145. Yamamoto F, Clausen H, White T, Marken J, Hakomori S. Molecular genetic basis of the histo-blood group ABO system. Nature. 1990;345(6272):229–233. doi:10.1038/345229a0. PMID 2333095
  146. Yazer M, Triulzi D, Sperry J, Corcos A, Seheult J. Rate of RhD-alloimmunization after the transfusion of RhD-positive red blood cell containing products among injured patients of childbearing age: single center experience and narrative literature review. Hematology. 2021;26(1):321–327. doi:10.1080/16078454.2021.1905395. PMID 33775237
  147. Yazer MH, Emery SP, Triulzi DJ, Spinella P, Leeper C. Another piece of the hemolytic disease of the fetus and newborn puzzle after RhD-positive transfusion in trauma resuscitation: the proportion of pregnant women who produce high titer anti-D. Trauma Surg Acute Care Open. 2024;9(Suppl 1):e001252. doi:10.1136/tsaco-2023-001252. PMID 38196928
  148. Ying Q, Lv D, Fu X, et al. Resolution of serologic problems due to cold agglutinin mediated autoimmune hemolytic anemia and its transfusion decision. J Clin Lab Anal. 2021;35(8):e23894. doi:10.1002/jcla.23894. PMID 34216510
  149. Yoon E, Kim TY, Kim H, Cho D. Evorpacept-induced interference and application of a novel mitigation agent, Evo-NR, in pretransfusion testing. Transfus Med Hemother. 2024;51(3):185–192. doi:10.1159/000534273. PMID 38867811
  150. Yu LC, Twu YC, Chang CY, Lin M. Molecular basis of the adult i phenotype and the gene responsible for the expression of the human blood group I antigen. Blood. 2001;98(13):3840–3845. doi:10.1182/blood.v98.13.3840. PMID 11739194
  151. Yurtsever N, Lee ES, Pinatti L, et al. Mixed-field ABO front typing as an early sign of disease recurrence in ABO-matched stem cell transplantation. Immunohematology. 2024;40(3):89–92. doi:10.2478/immunohematology-2024-013. PMID 39373301
  152. Zantek ND, Koepsell SA, Tharp DR Jr, Cohn CS. The direct antiglobulin test: a critical step in the evaluation of hemolysis. Am J Hematol. 2012;87(7):707–709. doi:10.1002/ajh.23218. PMID 22566278